<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">99462</article-id>
<article-id pub-id-type="doi">10.7554/eLife.99462</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.99462.2</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.2</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The novel role of Kallistatin in linking metabolic syndromes and cognitive memory deterioration by inducing amyloid-β plaques accumulation and tau protein hyperphosphorylation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Qi</surname>
<given-names>Weiwei</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n1">#</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Long</surname>
<given-names>Yanlan</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="author-notes" rid="n1">#</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Li</surname>
<given-names>Ziming</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="author-notes" rid="n1">#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Zhen</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shi</surname>
<given-names>Jinhui</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xie</surname>
<given-names>Wanting</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Laijian</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tan</surname>
<given-names>Yandan</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8517-5405</contrib-id>
<name>
<surname>Zhou</surname>
<given-names>Ti</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liang</surname>
<given-names>Minting</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Jiang</surname>
<given-names>Ping</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
<email>jiangp45@mail2.sysu.edu.cn</email>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Jiang</surname>
<given-names>Bin</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
<email>jiangb3@mail.sysu.edu.cn</email>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Yang</surname>
<given-names>Xia</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a6">6</xref>
<email>yangxia@mail.sysu.edu.cn</email>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8996-1470</contrib-id>
<name>
<surname>Gao</surname>
<given-names>Guoquan</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a7">7</xref>
<xref ref-type="aff" rid="a8">8</xref>
<xref ref-type="aff" rid="a9">9</xref>
<email>gaogq@mail.sysu.edu.cn</email>
</contrib>
<aff id="a1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0064kty71</institution-id><institution>Department of Biochemistry and molecular biology, Zhongshan School of Medicine, Sun Yat-sen University</institution></institution-wrap>, <city>Guangzhou</city>, <country country="CN">China</country></aff>
<aff id="a2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0064kty71</institution-id><institution>Advanced Medical Technology Center, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University</institution></institution-wrap>, <city>Guangzhou</city>, <country country="CN">China</country></aff>
<aff id="a3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gh4er46</institution-id><institution>Guangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences (CAS)</institution></institution-wrap>, <city>Shenzhen</city>, <country country="CN">China</country></aff>
<aff id="a4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0064kty71</institution-id><institution>Guangdong Province Key Laboratory of Brain Function and Disease, School of Medicine, Sun Yat-sen University</institution></institution-wrap>, <city>Shenzhen</city>, <country country="CN">China</country></aff>
<aff id="a5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0530pts50</institution-id><institution>Department of Clinical Medical Laboratory, Guangzhou First People Hospital, School of Medicine, South China University of Technology</institution></institution-wrap>, <city>Guangzhou</city>, <country country="CN">China</country></aff>
<aff id="a6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0064kty71</institution-id><institution>China Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education</institution></institution-wrap>, <city>Guangzhou</city>, <country country="CN">China</country></aff>
<aff id="a7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0064kty71</institution-id><institution>Guangdong Engineering &amp; Technology Research Center for Gene Manipulation and Biomacromolecular Products (Sun Yat-sen University)</institution></institution-wrap>, <city>Guangzhou</city>, <country country="CN">China</country></aff>
<aff id="a8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0064kty71</institution-id><institution>Guangdong Province Key Laboratory of Brain Function and Disease, Zhongshan School of Medicine, Sun Yat-sen University</institution></institution-wrap>, <city>Guangzhou</city>, <country country="CN">China</country></aff>
<aff id="a9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tm3k558</institution-id><institution>Guangdong Provincial Key Laboratory of Diabetology&amp; Guangzhou Municipal Key Laboratory of Mechanistic and Translational Obesity Research, Medical Center for Comprehensive Weight Control, The Third Affiliated Hospital of Sun Yat-sen University Guangzhou</institution></institution-wrap>, <city>Guangdong</city>, <country country="CN">China</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Ye</surname>
<given-names>Keqiang</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Chinese Academy of Sciences</institution>
</institution-wrap>
<city>Shenzhen</city>
<country>China</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Nelson</surname>
<given-names>Sacha B</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>Brandeis University</institution>
</institution-wrap>
<city>Waltham</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn id="n1" fn-type="equal"><label>#</label><p>These authors contributed equally to this study.</p></fn>
<fn fn-type="coi-statement"><p>Competing interests: No competing interests declared</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2024-08-13">
<day>13</day>
<month>08</month>
<year>2024</year>
</pub-date>
<pub-date date-type="update" iso-8601-date="2025-05-01">
<day>01</day>
<month>05</month>
<year>2025</year>
</pub-date>
<volume>13</volume>
<elocation-id>RP99462</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2024-05-20">
<day>20</day>
<month>05</month>
<year>2024</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2024-05-20">
<day>20</day>
<month>05</month>
<year>2024</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.05.20.594915"/>
</event>
<event>
<event-desc>Reviewed preprint v1</event-desc>
<date date-type="reviewed-preprint" iso-8601-date="2024-08-13">
<day>13</day>
<month>08</month>
<year>2024</year>
</date>
<self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.99462.1"/>
<self-uri content-type="editor-report" xlink:href="https://doi.org/10.7554/eLife.99462.1.sa3">eLife assessment</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.99462.1.sa2">Reviewer #1 (Public Review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.99462.1.sa1">Reviewer #2 (Public Review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.99462.1.sa0">Reviewer #3 (Public Review):</self-uri>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2024, Qi et al</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Qi et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-99462-v2.pdf"/>
<abstract>
<title>Abstract</title><p>Accumulation of amyloid β (Aβ) peptides and hyperphosphorylated tau proteins in the hippocampus triggers cognitive memory decline in Alzheimer’s disease (AD). The incidence and mortality of sporadic AD were tightly associated with diabetes and hyperlipidemia, while the exact linked molecular is uncertain. Here, we reported that serum Kallistatin concentrations were meaningfully higher in AD patients, with a higher concentration of fasting blood glucose and triglyceride. In addition, the constructed Kallistatin-transgenic (KAL-TG) mice defined its cognitive memory impairment phenotype and lower LTP in hippocampal CA1 neurons accompanied by increased Aβ deposition and tau phosphorylation. Mechanistically, Kallistatin could directly bind to the Notch1 receptor and thereby upregulate BACE1 expression by inhibiting PPARγ signaling, resulting in Aβ cleavage and production. Besides, Kallistatin could promote the phosphorylation of tau by activating GSK-3β. Fenofibrate, a hypolipidemic drug, could alleviate cognitive memory impairment by down-regulating Aβ and tau phosphorylation of KAL-TG mice. Collectively, our data clarified a novel mechanism for Aβ accumulation and tau protein hyperphosphorylation regulation by Kallistatin, which might play a crucial role in linking metabolic syndromes and cognitive memory deterioration, and suggested that fenofibrate might have the potential for treating metabolism-related AD.</p>
</abstract>
<abstract abstract-type="summary">
<title>Highlights</title>
<list list-type="bullet">
<list-item><p>Kallistatin-transgenic (KAL-TG) mice defined its cognitive memory impairment phenotype accompanied by increased Aβ deposition and tau phosphorylation.</p></list-item>
<list-item><p>Kallistatin could directly bind to the Notch1 receptor and thereby upregulate BACE1 expression by inhibiting PPARγ signaling.</p></list-item>
<list-item><p>Fenofibrate could alleviate cognitive memory impairment and down-regulate the serum Kallistatin level.</p></list-item>
</list>
</abstract>
<kwd-group kwd-group-type="author">
<title>Key words</title>
<kwd>Alzheimer’s disease</kwd>
<kwd>Kallistatin</kwd>
<kwd>Aβ42</kwd>
<kwd>BACE1</kwd>
<kwd>Diabetes</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>In response to the reviewers'comments, the current version has been updated as follows:
1. The immunohistochemical images have been replaced, and the brain regions used for statistical analysis have been standardized.
2. The statistical methods have been described in more detail.
3. The manuscript has been professionally edited for language and style.
</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Alzheimer’s disease (AD), the most prevalent irreversible neurodegenerative disorder associated with dementia in elderly individuals, is marked by a gradual decline in cognitive memory. Pathologically, AD is identified by the presence of extracellular amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles (NFTs) <sup><xref ref-type="bibr" rid="c1">1</xref>, <xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c3">3</xref></sup>. The Aβ cascade and tau protein hyperphosphorylation are the two primary hypotheses concerning AD. According to the Aβ cascade hypothesis, the excessive production of Aβ disrupts normal cellular functions, leading to synaptic dysfunction, neurodegeneration, tau hyperphosphorylation, and neuroinflammation, which ultimately result in memory impairment in individuals with AD and dementia <sup><xref ref-type="bibr" rid="c4">4</xref>, <xref ref-type="bibr" rid="c5">5</xref></sup>. Aβ peptides are derived from the sequential cleavage of amyloid precursor protein (APP) by β-secretase (β-site APP cleaving enzyme 1, BACE1) and γ-secretase, thus making this cleavage process significant in AD pathology <sup><xref ref-type="bibr" rid="c6">6</xref>, <xref ref-type="bibr" rid="c7">7</xref></sup>. BACE1 is considered a highly promising therapeutic target. Several potent BACE1 inhibitors have progressed to advanced stages in clinical trials, emphasizing the role of BACE1 in Aβ production <sup><xref ref-type="bibr" rid="c8">8</xref>, <xref ref-type="bibr" rid="c9">9</xref>, <xref ref-type="bibr" rid="c10">10</xref></sup>. Tau, a microtubule-associated protein, naturally occurs in axons and regulates microtubule dynamics and axonal transport <sup><xref ref-type="bibr" rid="c11">11</xref></sup>. In AD, tau undergoes a multistep transformation from a natively unfolded monomer to large aggregated forms, such as NFTs, another defining feature of AD <sup><xref ref-type="bibr" rid="c12">12</xref>, <xref ref-type="bibr" rid="c13">13</xref></sup>. Glycogen synthase kinase-3 (GSK3) is a key kinase involved in the initial steps of tau phosphorylation, with Wnt signaling being crucial in activating GSK-3β and GSK-3β-mediated tau phosphorylation <sup><xref ref-type="bibr" rid="c14">14</xref></sup>. The physiological mechanisms underlying their interaction remain poorly understood.</p>
<p>There is a close relationship between metabolic disorders and cognitive impairment across the AD spectrum <sup><xref ref-type="bibr" rid="c15">15</xref>, <xref ref-type="bibr" rid="c16">16</xref></sup>. Nearly 95% of AD patients are categorized as sporadic patients, whose increasing incidence and mortality are strongly associated with type 2 diabetes mellitus (T2DM), obesity, and hyperlipidemia <sup><xref ref-type="bibr" rid="c17">17</xref>, <xref ref-type="bibr" rid="c18">18</xref>, <xref ref-type="bibr" rid="c19">19</xref></sup>. About 37% of comorbidities between AD and diabetes have been reported in the Alzheimer’s Association Report <sup><xref ref-type="bibr" rid="c20">20</xref>, <xref ref-type="bibr" rid="c21">21</xref></sup>. As a result of the strong association and shared mechanism between AD and T2DM, AD has been termed “type 3 diabetes” by some researchers <sup><xref ref-type="bibr" rid="c22">22</xref>, <xref ref-type="bibr" rid="c23">23</xref>, <xref ref-type="bibr" rid="c24">24</xref>, <xref ref-type="bibr" rid="c25">25</xref></sup>. Several studies have demonstrated that diabetes confers a 1.6-fold increased risk of developing dementia <sup><xref ref-type="bibr" rid="c26">26</xref>, <xref ref-type="bibr" rid="c27">27</xref></sup>. Similarly, central obesity and high body mass index (BMI) during middle age are associated with an about 3.5-fold increased risk of dementia later in life <sup><xref ref-type="bibr" rid="c28">28</xref></sup>. Therefore, controlling blood glucose and lipids is expected to be a strategy for preventing or moderating cognitive decline during aging. Nevertheless, the exact link and key associated regulators between metabolic abnormalities and AD are still unclear.</p>
<p>Kallistatin is a serine proteinase inhibitor previously identified as a tissue kallikrein-binding protein <sup><xref ref-type="bibr" rid="c29">29</xref></sup>. It is produced predominantly in the liver and is widely expressed in body tissues, where it has antiangiogenic, antifibrotic, antioxidative stress, and antitumor effects <sup><xref ref-type="bibr" rid="c30">30</xref>, <xref ref-type="bibr" rid="c31">31</xref></sup>. Furthermore, Kallistatin was found to be increased in patients with obesity, prediabetes, and diabetes <sup><xref ref-type="bibr" rid="c32">32</xref>, <xref ref-type="bibr" rid="c33">33</xref>, <xref ref-type="bibr" rid="c34">34</xref></sup>. The concentration of Kallistatin was positively correlated with the triglyceride glucose index <sup><xref ref-type="bibr" rid="c35">35</xref></sup>, which was proven to be an independent risk factor for dementia <sup><xref ref-type="bibr" rid="c36">36</xref></sup>. In addition, our previous study revealed that the concentration of serum Kallistatin in T2DM patients was significantly increased and further revealed that Kallistatin suppressed wound healing in T2DM patients by promoting local inflammation, which suggested that Kallistatin plays a critical role in the progression of T2DM <sup><xref ref-type="bibr" rid="c37">37</xref></sup>. Furthermore, our recent research revealed that Kallistatin can cause memory and cognitive dysfunction by disrupting the glutamate-glutamine cycle<sup><xref ref-type="bibr" rid="c38">38</xref></sup>.</p>
<p>To explore the relationships among T2DM, AD and Kallistatin, we constructed Kallistatin transgenic (KAL-TG) mice to explore whether Kallistatin could cause cognitive impairment through the upregulation of Aβ production. Taken together, our results suggest that a novel regulatory mechanism of Aβ production and tau protein hyperphosphorylation by Kallistatin is involved in the progression of metabolic abnormality-related AD.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Kallistatin increases in AD patients and AD model mice</title>
<p>To explore the relevance of AD in T2DM, a GAD disease enrichment analysis was initially conducted on differentially expressed genes in neurons of T2DM patients and normal controls, revealing a close relationship between AD and T2DM (GSE161355) (<xref rid="figs1" ref-type="fig">Fig. S1A</xref>). Additionally, PFAM analysis using the DAVID database identified enrichment of the Serpin family protein domain (<xref rid="figs1" ref-type="fig">Fig. S1B</xref>) (<ext-link ext-link-type="uri" xlink:href="https://david.ncifcrf.gov/">https://david.ncifcrf.gov/</ext-link>). Our previous studies revealed that Kallistatin (serpin family a member 4) was elevated in the serum of T2DM patients and was associated with an adverse prognosis of diabetes complications <sup><xref ref-type="bibr" rid="c44">44</xref></sup>. We collected 11 serum samples from dementia patients at Sun Yat-sen Memorial Hospital and reported that the concentration of Kallistatin was greater than that in normal controls<sup><xref ref-type="bibr" rid="c38">38</xref></sup>. In this study, 56 AD patients and 61 healthy controls were enrolled from four hospitals in Guangdong Province to further investigate the potential relevance of Kallistatin and AD. The clinical and biochemical characteristics of the participants are provided in Tables S1 and S2. In addition, the serum Kallistatin (12.78 ±2.80 μg/mL) content in patients with AD was greater than that in normal controls (9.78 ±1.93 μg/mL) (<xref rid="fig1" ref-type="fig">Fig. 1A</xref>). Similarly, fasting blood glucose (FBG) and triglyceride (TG) levels were greater in AD patients than in healthy controls (<xref rid="fig1" ref-type="fig">Fig. 1B</xref>). We further grouped all the AD patients according to diabetes status and found that the Kallistatin (13.79 ±3.05 μg/mL) and TG contents were further elevated in AD patients with diabetes (<xref rid="fig1" ref-type="fig">Fig. 1C-D</xref>). Similarly, Kallistatin expression was increased in the hippocampus of the AD model mouse SAMP8 compared with that in the control mouse SAMR1 (<xref rid="figs1" ref-type="fig">Fig. S1C-D</xref>). Taken together, these results indicate that the Kallistatin concentration is increased in metabolic abnormality-related AD patients.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 1</label>
<caption><title>Increased Kallistatin was presented in AD patients and could impair cognitive memory in mice.</title>
<p>(A-B) Serum Kallistatin(A), fasting blood glucose (FBG), triglyceride (TG), and total cholesterol (TC) (B) of AD patients and their corresponding normal control subjects. (C-D) Serum Kallistatin(C), TG, and TC(D) of AD patients with DM and their corresponding normal control subjects (Student’s t-test). (E-J) The behavioral performance of KAL-TG mice was assessed through the Morris water maze test, Y-maze test, and electrophysiology. (E)The escape latency time of different months of KAL-TG mice (3M, 6M, 9M, 12M) and corresponding WT mice were presented during 1-6 day (two-way ANOVA). (F-H) Cognitive functions were evaluated by spatial probe test at day 7 (Student’s <italic>t</italic>-test), the representative each group mice traces were shown (F), then analyzing each group mice crossing platform times (G) and time percent in the targeted area (H), n=4 to 9 per group. (I) Spontaneous alternation of Y-maze test. (J) LTP was measured by whole-cell voltage-clamp recordings of CA1 neurons in acute hippocampal slices of KAL-TG (3M, 6M, 12M) and WT mice (Student’s t-test, n=6-12 cells from 3 mice per group). Error bars represent the standard deviation (SD); one asterisk, <italic>p</italic> &lt; 0.05, two asterisks, <italic>p</italic> &lt; 0.01; four asterisks, <italic>p</italic> &lt; 0.0001.</p></caption>
<graphic xlink:href="594915v2_fig1.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<sec id="s2b">
<title>Kallistatin impairs cognitive memory in mice</title>
<p>The above experiments demonstrated that Kallistatin was increased in AD patients and AD model mice. We subsequently generated KAL-TG mice and assessed their behavioral performance through the Morris water maze (MWM) and Y maze tests. Notably, the latency to escape the platform was longer, and the number of platform crossings, percentage of time spent, and spontaneous alternation were significantly lower in KAL-TG mice than in age-matched WT mice (<xref rid="fig1" ref-type="fig">Fig. 1E-I</xref>). Furthermore, long-term potentiation (LTP) was measured using whole-cell voltage-clamp recordings of CA1 neurons in acute hippocampal slices from KAL-TG and WT mice to assess changes in hippocampal synapses. The LTP in KAL-TG mice was significantly reduced compared to that in WT mice (<xref rid="fig1" ref-type="fig">Fig. 1J</xref>). These results showed that Kallistatin could impair cognitive memory in mice.</p>
</sec>
<sec id="s2c">
<title>Kallistatin promotes Aβ deposition and tau phosphorylation</title>
<p>We evaluated Aβ deposition and tau phosphorylation in these experimental mouse hippocampal tissues via immunohistochemistry (IHC) and western blotting. Predictably, the plaque density and tau phosphorylation in KAL-TG mice were much greater than those in age-matched WT mice (<xref rid="fig2" ref-type="fig">Fig. 2A-C</xref>, <xref rid="fig3" ref-type="fig">3A-D</xref>). Consistent with these results, ELISA detection of the Aβ42 content in hippocampal tissue revealed that Aβ production was extraordinarily increased in KAL-TG mice compared with WT mice (<xref rid="fig2" ref-type="fig">Fig. 2D</xref>). These results suggested that Kallistatin promoted Aβ deposition and tau phosphorylation.</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 2</label>
<caption><title>Kallistatin promoted Aβ generation.</title>
<p>(A-B) Immunohistochemistry staining of Aβ(A) was carried out in KAL-TG and WT mice hippocampal tissue. <italic>Scale bar</italic>, 100μm. The statistical analysis of Aβ plaques (B) in hippocampal tissue of KAL-TG and WT mice, n=4-5 per group. (C) Protein levels of Aβ were tested by western blot analysis in hippocampal tissue, n=3 per group, then statistically analyzed the above results. (D) Hippocampal tissue Aβ42 contents were performed by ELISA in KAL-TG and WT groups, n=3 per group. (E) Primary mouse neurons were isolated, then infected with adenovirus to overexpress Kallistatin for 72h. Aβ42 concentration of primary hippocampal neurons supernate and cell lysate were quantified by ELISA, n=3 per group. (F-G) Western blot analysis of Aβ protein level in primary hippocampal neurons infected with overexpressing Kallistatin adenovirus and control groups, then statistical analysis of Aβ protein levels, n=3 per group. Error bars represent the standard deviation (SD); one asterisk, <italic>p</italic> &lt; 0.05; two asterisks, <italic>p</italic> &lt; 0.01; three asterisks, <italic>p</italic> &lt; 0.001; Student’s <italic>t</italic>-test.</p></caption>
<graphic xlink:href="594915v2_fig2.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 3</label>
<caption><title>Kallistatin promoted tau phosphorylation.</title>
<p>(A-B) Immunohistochemistry staining of phosphorylated tau (p-tau S396, p-tau T231, p-tau S202) and tau(A) was carried out in KAL-TG and WT mice hippocampal tissue. Scale bar, 100μm. The statistical analysis of phosphorylated tau(B) in hippocampal tissue of KAL-TG and WT mice, n=3 per group. (C-D) Protein levels of phosphorylated tau (p-tau S396, p-tau T231, p-tau S202) and tau were tested by western blot analysis in hippocampal tissue, then statistically analyzed the above results. Error bars represent the standard deviation (SD); one asterisk, p &lt; 0.05; two asterisks, p &lt; 0.01; three asterisks, p &lt; 0.001; Student’s t-test.</p></caption>
<graphic xlink:href="594915v2_fig3.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<sec id="s2d">
<title>Kallistatin positively regulates Aβ generation by promoting β-secretase rather than γ-secretase</title>
<p>Western blot and ELISA analyses revealed that the Aβ levels in primary hippocampal neurons (immunofluorescence identified with the neural marker MAP2, <xref rid="figs2" ref-type="fig">Fig. S2G</xref>) infected with the Kallistatin adenovirus were greater than those in the control groups (<xref rid="fig2" ref-type="fig">Fig. 2E-G</xref>), as were those in the HT22 cells (<xref rid="figs2" ref-type="fig">Fig. S2A-C</xref>). Amyloid-beta precursor protein (APP) undergoes proteolytic processing to generate peptide fragments <sup><xref ref-type="bibr" rid="c45">45</xref></sup>. β-Secretase (BACE1) and γ-secretase, which are composed of presenilin 1 (PS1), nicastrin, and Pen-2, are crucial enzymes for Aβ generation <sup><xref ref-type="bibr" rid="c46">46</xref>, <xref ref-type="bibr" rid="c47">47</xref></sup>. We determined the levels of APP, BACE1, and PS1 in hippocampal tissue. Compared with those in WT mice, BACE1 protein and mRNA levels were greater in KAL-TG mice (<xref rid="fig4" ref-type="fig">Fig. 4A-C</xref>, <xref rid="figs2" ref-type="fig">S2D</xref>), whereas no significant difference in APP, PS1, or α-secretase (ADAM9, ADAM10, or ADAM17) expression was detected (<xref rid="fig4" ref-type="fig">Fig. 4A</xref>, <xref rid="figs2" ref-type="fig">S2E</xref>). Consistent with the above results, the activity of BACE1 increased (<xref rid="fig4" ref-type="fig">Fig. 4D</xref>), whereas PS1 activity did not change (<xref rid="figs2" ref-type="fig">Fig. S2F</xref>). Similarly, the expression and activity of BACE1 were found to be increased in primary mouse neurons and HT22 cells transfected with Kallistatin adenovirus (<xref rid="fig5" ref-type="fig">Fig. 5A-C</xref>, <xref rid="figs3" ref-type="fig">S3A-C</xref>), while PS1 expression and activity remained unchanged (<xref rid="fig5" ref-type="fig">Fig. 5A</xref>, <xref rid="fig5" ref-type="fig">5D</xref>, <xref rid="figs3" ref-type="fig">S3A</xref>). Additionally, the effect of Kallistatin was attenuated by the BACE1 inhibitor verubecestat or siBACE1 03, which was the most effective (<xref rid="fig5" ref-type="fig">Fig. 5E-F</xref>, <xref rid="figs3" ref-type="fig">S3D</xref>). These results indicate that Kallistatin can promote Aβ generation through the upregulation of BACE1 expression.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 4</label>
<caption><title>Kallistatin transgenic mice exhibited increased BACE1 expression and activity in the hippocampus.</title>
<p>(A) Western blot analysis of relevant proteins, such as APP, PS1, and BACE1 during Aβ generation in hippocampal tissue of each time point (6M, 9M, 12M) KAL-TG mice and corresponding WT control groups, n=3 per group, then statistical analysis of APP, PS1 and BACE1 protein levels. (B) Immunohistochemistry staining of BACE1 was carried out in KAL-TG and WT mice hippocampal tissue at each time point (6M, 9M, 12M). n=3 to 5 per group. <italic>Scale bar</italic>, 100 μm. (C) Statistical analysis of BACE1 immunohistochemistry staining, n=3 to 4 per group. (D) ELISA measured the β-secretase activity of each group’s hippocampal tissue, n=3 per group. Error bars represent the standard deviation (SD); one asterisk, <italic>p</italic> &lt; 0.05, two asterisks, <italic>p</italic> &lt; 0.01; Student’s t-test.</p></caption>
<graphic xlink:href="594915v2_fig4.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 5</label>
<caption><title>In <italic>vitro</italic>, Kallistatin promoted BACE1 expression to augment Aβ by suppressing PPARγ activation.</title>
<p>(A) The relevant protein levels in primary mouse neurons infected with overexpressing Kallistatin adenovirus during Aβ generation were determined by western blot analysis. (B) Statistical analysis of BACE1 expression in primary neurons. (C-D) β-secretase(C) and γ-secretase(D) activity of primary hippocampal neurons infected with overexpressing Kallistatin adenovirus and control adenovirus was measured by ELISA. (E) Primary hippocampal neurons were treated with BACE1 inhibitor verubecestat (50nM), then infected with adenovirus to overexpress Kallistatin. Western blot analysis of Aβ, BACE1, and Kallistatin protein levels, β-actin served as a loading control. (F) HT22 cells were infected with BACE1 siRNA, then infected with adenovirus to overexpress Kallistatin. Western blot analysis of Aβ and BACE1 protein levels, β-actin served as a loading control. (G) The relevant proteins involved in BACE1 transcriptional expressions, such as PPARγ, YY1, and SP1 were measured by western blot analysis in hippocampal tissue. β-actin served as a loading control. (H) Statistical analysis of PPARγ in hippocampal tissue of each group. (I) The representative diagrams of PPARγ expression in hippocampal tissue were presented in the above graphs. <italic>Scale bar</italic>, 100μm. (J) Statistical analysis of PPARγ immunohistochemistry staining in hippocampal tissue of each group, n=3 to 4 per group. (K)Primary hippocampal neurons were treated with PPARγ agonist rosiglitazone (10nM) for 12h, then infected with adenovirus to overexpress Kallistatin for 72h. Western blot analysis of Aβ and BACE1 protein levels. β-actin served as a loading control. (L) Statistical analysis of PPARγ protein levels in each group. Error bars represent the standard deviation (SD), one asterisk, <italic>p</italic> &lt; 0.05, two asterisks, <italic>p</italic> &lt; 0.01; three asterisks, <italic>p</italic> &lt; 0.001; ns means no significant difference; Student’s <italic>t</italic>-test.</p></caption>
<graphic xlink:href="594915v2_fig5.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<sec id="s2e">
<title>Kallistatin suppresses PPAR<bold>γ</bold> activation to promote BACE1 expression</title>
<p>The transcription factors SP1, YY1, and PPAR reportedly regulate BACE1 expression at the transcriptional level. Among them, PPARγ can downregulate BACE1 expression <sup><xref ref-type="bibr" rid="c48">48</xref>, <xref ref-type="bibr" rid="c49">49</xref>, <xref ref-type="bibr" rid="c50">50</xref></sup>. PPARγ decreased in the hippocampal tissue of KAL-TG mice, as detected by western blot and immunohistochemical analysis (<xref rid="fig5" ref-type="fig">Fig. 5G-J</xref>). However, no significant differences in YY1 or SP1 expression were detected (<xref rid="fig5" ref-type="fig">Fig. 5G</xref>). In addition, Kallistatin downregulated the expression of PPARγ in primary hippocampal neurons and HT22 cells, thus increasing BACE1 and Aβ expression (<xref rid="fig5" ref-type="fig">Fig. 5K</xref>, <xref rid="figs3" ref-type="fig">S3E</xref>). Treatment with rosiglitazone, a PPARγ agonist, reversed the decrease in PPARγ caused by Kallistatin (<xref rid="fig5" ref-type="fig">Fig. 5K-L</xref>). Predictably, rosiglitazone inhibited the ability of Kallistatin to promote BACE1 and Aβ (<xref rid="fig5" ref-type="fig">Fig. 5K</xref> and <xref rid="figs3" ref-type="fig">Fig. S3E</xref>).</p>
</sec>
<sec id="s2f">
<title>Kallistatin promotes Aβ production <italic>via</italic> direct binding to the Notch1 receptor and activating the Notch1 pathway</title>
<p>Our results indicated that Notch1 was highly expressed in the hippocampal tissues of KAL-TG mice (<xref rid="fig6" ref-type="fig">Fig. 6A-D</xref>). Furthermore, Notch1 expression was upregulated in primary hippocampal neurons and HT22 cells infected with adenovirus expressing Kallistatin <italic>in vitro</italic> (<xref rid="figs4" ref-type="fig">Fig. S4A-B</xref>). Additionally, Kallistatin could directly bind to the Notch1 receptor and activate the Notch1 pathway (<xref rid="fig6" ref-type="fig">Fig. 6E-F</xref> and <xref rid="figs4" ref-type="fig">Fig. S4C-D</xref>). Treatment with siNotch1 03, which was the most effective (<xref rid="figs4" ref-type="fig">Fig. S4E</xref>), to knock down Notch1 inhibited the effect of Kallistatin on the activation of the Notch1 signaling pathway, leading to the downregulation of HES1, upregulation of PPARγ, and downregulation of BACE1 and Aβ (<xref rid="fig6" ref-type="fig">Fig. 6G</xref>). HES1, an essential downstream effector of the Notch1 signaling pathway, has been reported to suppress the expression of <italic>PPARG</italic> (the gene name of PPARγ) in neurons <sup><xref ref-type="bibr" rid="c51">51</xref>, <xref ref-type="bibr" rid="c52">52</xref></sup>. Similarly, HES1 shRNA 1, the most effective (<xref rid="figs4" ref-type="fig">Fig. S4F</xref>), upregulated PPARγ and decreased the production of BACE1 and Aβ when neurons were infected with adenovirus to overexpress Kallistatin (<xref rid="fig6" ref-type="fig">Fig. 6H</xref>). These results suggest that Kallistatin promotes Aβ production <italic>via</italic> direct binding to the Notch1 receptor and activating the Notch1 pathway.</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 6</label>
<caption><title>Kallistatin directly bonded to the Notch1 receptor, which activated the Notch1 pathway to promote Aβ production.</title>
<p>(A) Notch1 expression was measured by western blot analysis in hippocampal tissue. β-actin served as a loading control. (B) Statistical analysis of Notch1 in hippocampal tissue of each group. (C) The representative diagrams of Nocth1 expression in hippocampal tissue were presented in the above graphs. Scale bar, 100μm. (D) Statistical analysis of Notch1 immunohistochemistry staining in hippocampal tissue of each group. (E-F) Primary hippocampal neurons were infected with overexpressing Kallistatin adenovirus for 72h, then Co-IP analysis (E) and membrane extraction experiment (F) was performed to verify whether Kallistatin can bind to the Notch1 receptor. β-actin served as a loading control. (G-H) HT22 cells were treated with siRNA (Notch1) and shRNA (HES1) to knock down Notch1 and HES1 for 12h, then infected with adenovirus to overexpress Kallistatin for 24h. Western blot analysis was used to detect the Notch1 signaling pathway. Error bars represent the standard deviation (SD), one asterisk, <italic>p</italic> &lt; 0.05; Student’s t-test.</p></caption>
<graphic xlink:href="594915v2_fig6.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<sec id="s2g">
<title>Kallistatin promotes the phosphorylation of tau by activating the Wnt signaling pathway</title>
<p>Glycogen synthase kinase3-β (GSK-3β) is a crucial element in the phosphorylation of tau <sup><xref ref-type="bibr" rid="c53">53</xref></sup>. When Wnt signaling is activated, the LRP6 PPPSPxS motif can directly interact with GSK-3β and phosphorylate it <sup><xref ref-type="bibr" rid="c54">54</xref></sup>. Consequently, when Wnt signaling is inhibited, GSK-3β becomes activated and dephosphorylated, allowing nonphosphorylated GSK-3β to add phosphate groups to serine/threonine residues of tau <sup><xref ref-type="bibr" rid="c14">14</xref></sup>. Kallistatin has already been reported as a competitive inhibitor of the canonical Wnt signaling pathway <sup><xref ref-type="bibr" rid="c55">55</xref></sup>. Consistent with previous reports, our results demonstrated that GSK-3β was activated in the hippocampus of KAL-TG mice (<xref rid="fig7" ref-type="fig">Fig. 7A-B</xref>). Moreover, an increase in tau phosphorylation was observed with the activation of GSK-3β induced by Kallistatin overexpression (<xref rid="fig7" ref-type="fig">Fig. 7C-D</xref>, <xref rid="figs5" ref-type="fig">Fig. S5A</xref>), which was reversed by LiCl, an inhibitor of GSK-3β (<xref rid="fig7" ref-type="fig">Fig. 7E-F</xref>, <xref rid="figs5" ref-type="fig">Fig. S5B</xref>). These findings confirmed that Kallistatin promoted tau phosphorylation by activating the Wnt signaling pathway.</p>
<fig id="fig7" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 7</label>
<caption><title>Kallistatin promoted phosphorylation of tau by suppressing Wnt signaling pathway.</title>
<p>(A-B) GSK-3β and p-GSK-3β expression was measured by western blot analysis in hippocampal tissue, then statistically analyzed the above results. (C-D) Primary hippocampal neurons were treated with overexpressing Kallistatin adenovirus for 72h, then western blot analysis was used to detect the content of GSK-3β, p-GSK-3β, tau, p-tau (Ser9, T231, S396), and statistically analyzed the above results. (E-F) Primary hippocampal neurons were treated with overexpressing Kallistatin adenovirus for 48h, then treated with LiCl (10mM) for 24h, western blot analysis was used to detect the content of GSK-3β, p-GSK-3β, p-tau (Ser9, T231, S396), and statistical analysis of the above results. Error bars represent the standard deviation (SD), two asterisk, p &lt; 0.01; three asterisk, p &lt; 0.001; Student’s t-test.</p></caption>
<graphic xlink:href="594915v2_fig7.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<sec id="s2h">
<title>Fenofibrate alleviates memory and cognitive impairment in KAL-TG mice</title>
<p>Hyperlipidemia and hyperlipidemia account for the development of AD <sup><xref ref-type="bibr" rid="c56">56</xref>, <xref ref-type="bibr" rid="c57">57</xref></sup>. Here, a hypolipidemic drug (fenofibrate) and a hypoglycemic drug (rosiglitazone) were used to treat KAL-TG mice (<xref rid="fig8" ref-type="fig">Fig. 8A</xref>). Compared with that of the KAL-TG group, the behavioral performance of the treated group was improved, as measured by the MWM and Y-maze tests. The latency to reach the escape platform on the fifth training day was significantly decreased (<xref rid="fig8" ref-type="fig">Fig. 8B</xref>), and the number of platform crossings (<xref rid="fig8" ref-type="fig">Fig. 8C</xref>), percentage of time spent (<xref rid="fig8" ref-type="fig">Fig. 8D</xref>), and spontaneous alternation (<xref rid="fig8" ref-type="fig">Fig. 8F</xref>) were significantly greater in the fenofibrate-treated group than in the rosiglitazone-treated group. Similarly, the path trace heatmap indicated that the mice in the fenofibrate-treated group stayed in the target quadrant longer (<xref rid="fig8" ref-type="fig">Fig. 8E</xref>). In addition, decreased serum Kallistatin levels, Aβ and BACE1 levels, phosphorylation of tau, and activation of GSK3β were detected in the fenofibrate-treated KAL-TG group (<xref rid="fig8" ref-type="fig">Fig. 8G-K</xref>). However, there was no significant difference between the rosiglitazone-treated group and the KAL-TG group (<xref rid="fig8" ref-type="fig">Fig. 8G-K</xref>).</p>
<fig id="fig8" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 8</label>
<caption><title>Fenofibrate could alleviate memory and cognitive impairment of KAL-TG mice.</title>
<p>(A) Illustration of experimental protocols. Fenofibrate (0.3 g/kg/d × 5week, i.g.) or rosiglitazone (5mg/kg/d × 5week, i.g.) were given to KAL-TG mice. The serum for Kallistatin measuring was collected at week 0 and week 4. And Morris water maze and Y-maze test were performed at week 5. (B-E) Behavioral performance was assessed through the Morris water maze test and the Y-maze test. (B) The escape latency time was presented during 1-5 day. (C-E) Cognitive functions were evaluated by spatial probe test at day 6, then analyzing each group of mice crossing platform times(C), time percent in the targeted area (D), and the path traces heatmap (E), n=5 to 6 per group. (F) Spontaneous alternation of Y-maze test. (G) Kallistatin decreased ratio was calculated by dividing the serum Kallistatin concentration of KAL-TG mice before Fenofibrate/ rosiglitazone treatment by the serum Kallistatin concentration of KAL-TG mice after a-month treatment, and serum Kallistatin concentration was measured by ELISA. (H-I) Protein levels of Aβ and BACE1 were tested by western blot analysis in hippocampal tissue, then statistically analyzing the above results. (J-K) Protein levels of p-tau(231), tau, p-GSK-3β(Ser9) and GSK-3β were tested by western blot analysis in hippocampal tissue, then statistically analyzing the above results. Error bars represent the standard deviation (SD); one asterisk, <italic>p</italic> &lt; 0.05; Student’s t-test.</p></caption>
<graphic xlink:href="594915v2_fig8.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<sec id="s2i">
<title>Mechanism summary</title>
<p>In patients with metabolic abnormality-related AD, the concentration of Kallistatin is elevated, which could increase Aβ deposition through the Notch1/HES1/PPARγ/BACE1 pathway and induce tau hyperphosphorylation by activating GSK-3β. Consequently, elevated Kallistatin impaired cognitive memory by inducing Aβ deposition and tau hyperphosphorylation (<xref rid="figs5" ref-type="fig">Fig. S5C</xref>).</p>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>This study demonstrated that Kallistatin is a novel regulator of amyloid-β plaque accumulation, tau protein hyperphosphorylation, and metabolic abnormality-related cognitive memory impairment. It was shown that Kallistatin levels were increased in the serum of patients with AD and diabetes-related AD, as well as in the hippocampus of AD model mice. Additionally, the KAL-TG mice exhibited cognitive memory impairment and lower LTP in hippocampal CA1 neurons, along with increased Aβ deposition and tau phosphorylation. Mechanistically, Kallistatin transcriptionally upregulates BACE1 expression by suppressing the transcriptional repressor PPARγ, leading to Aβ cleavage and production. Most importantly, our studies revealed that Kallistatin could bind directly to the Notch1 receptor and activate the Notch1/HES1 pathway, causing a decrease in PPARγ, overproduction of BACE1, and increased Aβ42 generation. Moreover, Kallistatin can induce tau phosphorylation by activating GSK-3β, which results from the inhibition of LRP6. Finally, prolonged stimulation with high concentrations of Kallistatin impaired cognitive memory in mice. Finally, the hypolipidemic drug fenofibrate decreased Aβ expression, tau phosphorylation, and the serum Kallistatin level in KAL-TG mice, alleviating memory and cognitive impairment. For the first time, these observations establish an association between high Kallistatin levels and metabolic abnormality-related AD and provide a new drug candidate (fenofibrate) for AD patients with metabolic syndromes.</p>
<p>Increasing evidence suggests that diabetes mellitus and AD are closely linked. About 80% of AD patients are insulin resistant or have T2DM <sup><xref ref-type="bibr" rid="c58">58</xref></sup>; additionally, T2DM patients have a higher risk of up to 73% dementia than healthy controls do <sup><xref ref-type="bibr" rid="c26">26</xref></sup>. In line with these observations, the process of cognitive decline in T2DM patients appears to begin in the prediabetic phase of insulin resistance <sup><xref ref-type="bibr" rid="c59">59</xref>, <xref ref-type="bibr" rid="c60">60</xref></sup>. A GAD disease enrichment analysis of differentially expressed genes in the neurons of T2DM patients and normal controls revealed a close relationship between AD and T2DM. Additionally, PFAM analysis identified an enrichment of the Serpin family protein domain (<xref rid="figs1" ref-type="fig">Fig. S1A</xref>, B). We and other researchers reported that the level of Kallistatin (which belongs to the serpin family) was increased in T2DM patients <sup><xref ref-type="bibr" rid="c32">32</xref>, <xref ref-type="bibr" rid="c37">37</xref></sup>. Although the relationship between Kallistatin and AD has not been reported to date, we speculate that Kallistatin might be a critical molecule that could establish a relationship between Alzheimer’s disease and diabetes. Our data indicated that AD patients exhibit metabolic disorders and elevated Kallistatin levels (<xref rid="fig1" ref-type="fig">Fig. 1A-D</xref>, <xref rid="figs1" ref-type="fig">S1C-D</xref>). Additionally, KAL-TG mice showed impaired memory, cognitive function, and synaptic plasticity (<xref rid="fig1" ref-type="fig">Fig. 1E-J</xref>). These results suggest that Kallistatin represents a novel connection between AD and diabetes.</p>
<p>A hallmark of AD is the aggregation of Aβ into amyloid plaques and tau phosphorylation in patients’ brains. Aβ, a small peptide with a high propensity to form aggregates, is widely believed to be central and initial to the pathogenesis of this disease <sup><xref ref-type="bibr" rid="c61">61</xref></sup>. Correspondingly, it was discovered that Kallistatin could lead to Aβ overproduction through the Notch1/HES1/PPARγ/BACE1 signaling pathway. GSK-3β, a vital kinase that regulates the process of tau phosphorylation <sup><xref ref-type="bibr" rid="c53">53</xref></sup>, can be activated by inhibiting the Wnt signaling pathway. Kallistatin has been identified as a competitive inhibitor of LRP6, the Wnt receptor <sup><xref ref-type="bibr" rid="c55">55</xref></sup>. Consistent with previous reports, Kallistatin increased tau phosphorylation by activating GSK-3β. It was demonstrated for the first time that Kallistatin promoted AD by increasing Aβ production and tau phosphorylation in the central nervous system.</p>
<p>Previous studies have shown that Notch signaling is closely related to AD. For example, a NOTCH mutation was reported to cause AD-like pathology <sup><xref ref-type="bibr" rid="c62">62</xref></sup>. In addition, the level of Notch1 was found to be increased in AD patients <sup><xref ref-type="bibr" rid="c63">63</xref></sup>. In addition, the Notch1/HES1 signaling pathway has been reported to suppress the expression of PPARγ <sup><xref ref-type="bibr" rid="c64">64</xref></sup>. Our previous studies demonstrated that Kallistatin can activate Notch1 signaling <sup><xref ref-type="bibr" rid="c37">37</xref></sup>. Consequently, we detected Notch1 in our animal and cell models. Indeed, Notch1 was upregulated by Kallistatin (<xref rid="fig6" ref-type="fig">Fig. 6</xref>, <xref rid="figs4" ref-type="fig">S4</xref>), as was Aβ deposition. Notch signaling is initiated by receptor-ligand interactions at the cell surface. In mammals, there are five ligands encoded by JAG1, JAG2, DLL1, DLL3, and DLL4 <sup><xref ref-type="bibr" rid="c65">65</xref></sup>. Here, our results revealed that Kallistatin could activate Notch1 by binding directly to it, indicating that Kallistatin is a new ligand of the Notch1 receptor.</p>
<p>The treatment of AD has always been a prominent and challenging issue in neurology. Multiple strategies have been proposed to reduce the pathogenicity of Aβ and tau. Unfortunately, several Aβ-targeted therapies tested in phase III clinical trials have failed to slow cognitive decline, although they can effectively reduce the Aβ load <sup><xref ref-type="bibr" rid="c66">66</xref>, <xref ref-type="bibr" rid="c67">67</xref>, <xref ref-type="bibr" rid="c68">68</xref>, <xref ref-type="bibr" rid="c69">69</xref>, <xref ref-type="bibr" rid="c70">70</xref>, <xref ref-type="bibr" rid="c71">71</xref></sup>. BACE1 inhibitors have not only failed to improve the cognitive function of AD patients but have also resulted in clinical deterioration and liver function impairment <sup><xref ref-type="bibr" rid="c72">72</xref>, <xref ref-type="bibr" rid="c73">73</xref>, <xref ref-type="bibr" rid="c74">74</xref></sup>. Two possible reasons for the failure of clinical trials with BACE1 inhibitors are: first, the reduction in BACE1 activity could lead to the accumulation of full-length APP <sup><xref ref-type="bibr" rid="c75">75</xref></sup>; second, the size of the BACE1 active site is relatively large, and the use of a small molecule may not be sufficient to occupy the active site <sup><xref ref-type="bibr" rid="c76">76</xref></sup>. Consequently, synaptic damage caused by BACE1 inhibitors or their insufficient effect may lead to the failure of clinical trials. Therapeutic strategies targeting tau include tau aggregation blockers (TRx0014, TRx0237), antibody vaccine therapy (e.g., RO7105705, BIIB092), the inhibition of tau phosphorylation (Anavex2-73), and the use of microtubule stabilizers (Anavex2-73) <sup><xref ref-type="bibr" rid="c77">77</xref></sup>. Some of these drugs have been partially discontinued, while others are still undergoing clinical testing and have shown protective benefits. Nonetheless, several obstacles remain to the commercialization of tau treatments when they reach maturity.</p>
<p>Because of the failure of clinical trials, some researchers have proposed alternative options for AD therapeutics to address modifiable risk factors for the development of AD, such as type 2 diabetes <sup><xref ref-type="bibr" rid="c78">78</xref>, <xref ref-type="bibr" rid="c79">79</xref>, <xref ref-type="bibr" rid="c80">80</xref></sup>. Previous studies revealed that Kallistatin is a multifunctional protein strongly associated with diabetes and that a Kallistatin neutralizing antibody improves diabetic wound healing <sup><xref ref-type="bibr" rid="c44">44</xref></sup>. This study demonstrated that Kallistatin induced memory-related cognitive dysfunction by promoting Aβ deposition and tau phosphorylation. Thus, it is speculated that increased Kallistatin could be a promising candidate for T2DM-related AD therapy. PPARγ is a ligand-activated transcription factor and a master modulator of glucose and lipid metabolism, organelle differentiation, and inflammation <sup><xref ref-type="bibr" rid="c81">81</xref>, <xref ref-type="bibr" rid="c82">82</xref></sup>. Growing evidence revealed that PPARγ agonists (rosiglitazone) could rescue memory impairment of AD model mice <sup><xref ref-type="bibr" rid="c83">83</xref>, <xref ref-type="bibr" rid="c84">84</xref>, <xref ref-type="bibr" rid="c85">85</xref></sup>. In clinical trials, it is controversial whether rosiglitazone has a protective effect on memory cognitive function <sup><xref ref-type="bibr" rid="c86">86</xref>, <xref ref-type="bibr" rid="c87">87</xref>, <xref ref-type="bibr" rid="c88">88</xref></sup>. In this study, although Aβ expression had a downward trend, the memory and cognition of KAL-TG mice were unchanged after treatment with rosiglitazone for a month (<xref rid="fig8" ref-type="fig">Fig.8</xref>). This might be caused by insufficient treatment time and the unchanged Kallistatin level.</p>
<p>Fenofibrate is a fibric acid derivative for clinically lowering blood lipids, mainly triglycerides <sup><xref ref-type="bibr" rid="c89">89</xref></sup>. Studies showed that fenofibrate could prevent memory disturbances, maintain hippocampal neurogenesis, and protect against Parkinson’s disease (PD) <sup><xref ref-type="bibr" rid="c90">90</xref>, <xref ref-type="bibr" rid="c91">91</xref></sup>. Specifically, fenofibrate has a neuroprotective effect on memory impairment induced by Aβ through targeting α- and β-secretase <sup><xref ref-type="bibr" rid="c92">92</xref></sup>. Recently, our study proved that the fenofibrate could repair the disrupted glutamine-glutamate cycle by upregulating glutamine synthetase, while there is currently no fenofibrate treatment of AD in clinical trials<sup><xref ref-type="bibr" rid="c38">38</xref></sup>. In this study, we proved fenofibrate was beneficial for memory and cognitive impairment of KAL-TG mice. In addition, Aβ, BACE1, phosphorylated tau, and serum Kallistatin level of KAL-TG mice could be downregulated after the treatment of fenofibrate. All of these suggested that fenofibrate might be helpful for metabolic abnormalities-related AD patients. Therefore, fenofibrate administration in patients with metabolic syndrome play an early role in preventing and treating AD.</p>
<p>In summary, we affirmed that Kallistatin concentrations were increased in diabetes-related AD patients. In addition, our study demonstrated for the first time that Kallistatin positively regulated Aβ42 through Notch1/HES1/PPARγ/BACE1, and increased phosphorylated tau through inhibition of the Wnt signaling pathway. Kallistatin might play a crucial role in linking diabetes and cognitive memory deterioration. Moreover, fenofibrate could decrease the serum Kallistatin level, BACE1, Aβ, and phosphorylated tau of KAL-TG mice, leading to alleviating memory and cognitive impairment. These findings might provide new insight into AD and possibly other neurodegenerative disorders.</p>
</sec>
<sec id="s4">
<title>Materials and methods</title>
<sec id="s4a" sec-type="ethics-statement">
<title>Ethics approval and consent to participate</title>
<p>All patients involved in this study gave their informed consent. This study obtained the institutional review board approval of Medical Ethics of Zhongshan Medical College No. 072 in 2021 and Animal Experiment Ethics of Zhongshan Medical College, Approval No.: SYSU-IACUC-2019-B051.</p>
</sec>
<sec id="s4b">
<title>Human Subjects</title>
<p>The study was approved by the experimental ethics committee of Guangdong Academy of Medical Sciences and Sun Yat-sen University and carried out in strict accordance with the ethical principles, and each participant was provided written informed consent before collecting samples. We certify that the study was performed in accordance with the 1964 declaration of HELSINKI and later amendments. We collected 61 normal human samples, 56 AD patient samples, of whom 36 normal human samples were from the Zhongshan City People’s Hospital; 14 normal human samples and 22 AD patient samples were from Zhongshan Third People’s Hospital; 11 normal human samples and 14 AD patient samples were from Sun Yat-sen Memorial Hospital. AD patient was clinically diagnosed according to ICD-10 (International Classification of Diseases) and NINCDS-ADRDA (the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association) criteria, and 20 AD patient samples were clinically diagnosed according to MMSE (Mini-Mental State Examination), were collected from Guangdong Provincial People’s Hospital. All subjects’ Clinical characteristics were presented in Supplementary Tables (Table S1-2).</p>
</sec>
<sec id="s4c">
<title>Experimental Animals and Protocols</title>
<p>All animal experiment procedures were carried out in an environment without specific pathogens (Specific pathogen free, SPF) with the approval of the Animal Care and Use Committee of Sun Yat-sen University (approval ID: SYXK 2015-0107). The wild type mice (WT, C57BL/6) were purchased from the Animal Center of Guangdong Province (Production license No.: SCXK 2013-0002, Guangzhou, China). The SAMR1 and SAMP8 mice (7 months old) were purchased from Tianjin University of Traditional Chinese Medicine (Tianjin, China). Kallistatin transgenic mice (KAL-TG) were C57BL/6 strain provided by Dr. Jianxing Ma (University of Oklahoma Health Sciences Center) <sup><xref ref-type="bibr" rid="c39">39</xref></sup>. The KAL-TG mice genotype was identified by PCR technology (forward primer: 5’-AGGGAAG-ATTGTGGATTTGG-3’, reverse primer: 5’-ATGAAGATACCAGTGATGCTC-3’). KAL-TG mice aged 6 months were randomly divided into three groups: control group (KAL-TG), fenofibrate-treated group (KAL-TG-Feno, 0.3 g/kg/d), and rosiglitazone-treated group (KAL-TG-RSG, 0.005 g/kg/d). Fenofibrate (Sigma-Aldrich, cat. no. F6020) and rosiglitazone (Selleck, cat. no. S2556) were administered to mice by oral gavage. In three groups, the serum Kallistatin were examined in the 0 week and 4 week after drug treatment from the blood taken from mouse orbit. In addition, the Morris water maze and Y-maze test were performed one week after the second blood collection.</p>
</sec>
<sec id="s4d">
<title>Morris water maze (MWM)</title>
<p>The KAL-TG and WT mice were employed for the Morris water maze test including the behavioral test, latency experiment (for 6 days), and the probe test (the 7th day). In addition, the MWM was performed as described previously <sup><xref ref-type="bibr" rid="c40">40</xref></sup>. Mice were brought into the testing room and handled for 1 day before the training experiment. In the 6-day training experiment, each mouse was trained with four daily trials. The mice facing the wall were placed into the maze, exploring the maze from different directions (east, south, west, and north). This trial was completed as soon as the mouse found the platform, or 90 s elapsed. If the mice could discover and climb the submerged platform within 90 s, the system would automatically record the latency time and path immediately, and then the mouse was guided to and placed on the submerged platform for extra 20 s. On day 7, the platform was removed, and a probe test was performed to examine the strength and integrity of the animal spatial memory 24 h after the last testing trial. During the probe test, the mice were gently brought into the water from the fixed monitoring point, and the mice were allowed to swim for 90 s without the platform. Finally, all of the measured behavioral parameters were analyzed using SMART software.</p>
</sec>
<sec id="s4e">
<title>Y-maze test</title>
<p>A Y maze test was performed to assess the mice’s spatial memory. The Y maze was separated by 120°, consisting of three identical arms (30 cm long, 7 cm wide, and 15 cm high) made of blue PVC. The mice were placed first in one of the arms, and over the next 10 minutes, the sequence and number of their entry into the three arms were monitored. An alternation is defined when a mouse visits three straight arms (namely, ABC, BCA, or CAB, but not ABA, BAB, or CAC). Spontaneous alternation (%)=[(number of alternations)/(total number of arms−2)]×100.</p>
</sec>
<sec id="s4f">
<title>Electrophysiology</title>
<p>Hippocampal slices (300-400 μm) from KAL-TG and WT mice were cut as described <sup><xref ref-type="bibr" rid="c41">41</xref></sup>. Coronal slices from hippocampus (400 μm thick) were prepared from different age groups KAL-TG mice and their WT littermates using a tissue slicer (Vibratome 3000; Vibratome) in ice-cold dissection buffer containing the following (in mM): 212.7 sucrose, 3 KCl, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 3 MgCl<sub>2</sub>, 1 CaCl<sub>2</sub>, 26 NaHCO<sub>3</sub>, and 10 dextrose, bubbled with 95% O<sub>2</sub>/5% CO<sub>2</sub>. The slices were immediately transferred to ACSF at 35 °C for 30 min before recordings. The recipe of ACSF was similar to the dissection buffer, except that sucrose was replaced with 124 mM NaCl, and the concentrations of MgCl<sub>2</sub> and CaCl<sub>2</sub> were changed to 1 mM and 2 mM, respectively. All recordings were performed at 28-30 °C. Pyramidal cells in CA1 areas were identified visually under infrared differential interference contrast optics based on their pyramidal somata and prominent apical dendrites. Whole-cell was performed using an Integrated Patch-Clamp Amplifier (Sutter Instrument, Novato, CA, USA) controlled by Igor 7 software (WaveMetrics, Portland, OR, USA) filtered at 5 kHz and sampled at 20 kHz. Igor 7 software was also used for acquisition and analysis. Only cells with series resistance &lt;20 MΩ and input resistance &gt;100 MΩ were studied. Cells were excluded if input resistance changed &gt;15% or series resistance changed &gt;10% over the experiment. A concentric bipolar stimulating electrode with a tip diameter of 125 μm (FHC) was placed in the stratum radiatum. The recording and stimulating electrode distances were kept at 50-100 μm. Patch pipettes (2-4MΩ) were filled with the internal solution consisting of the following (in mM): 120 Cs-methylsulfonate, 10 Na-phosphocreatine, 10 HEPES, 4 ATP, 5 lidocaine N-ethyl bromide (QX-314), 0.5 GTP; the pH of the solution was 7.2–7.3, and the osmolarity was 270-285 mOsm.</p>
<p>To induce LTP, a pairing protocol was applied. In brief, conditioning stimulation consisted of 360 pulses at 2 Hz paired with continuous postsynaptic depolarization (180 s) to 0 mV. 50 μM picrotoxin was added to the recording bath to suppress excessive polysynaptic activity, and the concentration of Ca<sup>2+</sup> and Mg<sup>2+</sup> was elevated to 4 mM to reduce the recruitment of polysynaptic responses. A test pulse was delivered at 0.067 Hz to monitor baseline amplitude for 10 min before and 30 min following paired stimulation. To calculate LTP, the EPSC amplitude was normalized to the mean baseline amplitude during 10 min baseline. Potentiation was defined as the mean normalized EPSC amplitude 25–40 min after paired stimulation.</p>
</sec>
<sec id="s4g">
<title>ELISA</title>
<p>To quantify serum Kallistatin, the collected samples were centrifuged at 4 °C for 10min at 5000 rpm. It was detected using the KBP ELISA kit (#DY1669, R&amp;D systems, MN, USA) as per the instructions of the manufacturer. The levels of Aβ42 in brain tissue produced from mouse primary neuron cells and HT22 cells were measured with a mouse Aβ42 Elisa Kit (27721, IBL, Germany). To measure Aβ42 in brain tissue, 0.05 g of mouse brain tissues were weighed and homogenized using 2ml PBS with a protease inhibitor (cocktail, IKM1020, Solarbio). After centrifugalization at 4 °C for 30 min at 12000 g, the extracts’ supernatants were analyzed using the ELISA method after total protein quantification. To quantify levels of Aβ42 produced from primary neuron cells, the cell supernatants were ultrafiltrated with an Ultrafiltration tube (4-kD Millipore), centrifugalization, and testing. Cell homogenate was prepared in 1ml PBS with cocktail and quantified using the BCA method before being measured by ELISA.</p>
</sec>
<sec id="s4h">
<title>Immunohistochemistry</title>
<p>Tissue slices were prepared as described before <sup><xref ref-type="bibr" rid="c42">42</xref></sup>. The sections were incubated with Aβ (ab201060, Abcam, Cambridge, UK), BACE1 (#5606S, Cell Signaling Technology, Boston, USA), PPARγ (#2435, Cell Signaling Technology, Boston, USA), Notch1 (#3608, Cell Signaling Technology, Boston, USA), p-tau S202 (ab108387, Abcam, Cambridge, UK), p-tau T231(ab151559, Abcam, Cambridge, UK), p-tau S396 (ab109390, Abcam, Cambridge, UK), tau (ab75714, Abcam, Cambridge, UK) antibodies overnight at 4°C and then incubated with Alexa Fluor 488-donkey anti-rabbit IgG (H + L) (1:200, Life Technologies, Gaithersburg, MD, USA, #A21208) for 1h, then incubated with a biotin-conjugated secondary antibody for 30 min, followed by incubation with DAB for 10 s and hematoxylin staining for 30 s. The IHC signals were analyzed using ImageJ.</p>
</sec>
<sec id="s4i">
<title>Cell culture experiments</title>
<p>HT22 cells were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). HT22 cells were cultured and grown to confluence in DMEM supplemented with 10% FBS (Gibco BRL), 100 U/mL penicillin, and 100 U/mL streptomycins (Gibco BRL).</p>
</sec>
<sec id="s4j">
<title>Primary culture of hippocampal neurons</title>
<p>Primary neurons were obtained from the hippocampus of C57/BL6J mice at age 1-3 days. Before culturing, the newborn pup was euthanized and dipped into 70% ethanol for 3 min. First, the infant pup hippocampus was isolated with eye tweezers observed under the stereomicroscope, and excess soft tissue was removed. Second, hippocampal tissue in PBS buffer was cut up with scissors gently and blown with a 1ml pipette until it was not visible. Next, the cell suspension was transferred to a 15ml centrifuge tube and centrifuged at 1000 rpm for 5 min at room temperature. Cell precipitation was suspended and cultured with 2-3mL primary neural stem cell (NSC) suspension (Thermo Fisher Scientific, 21103049) in a 37 °C, 5% CO<sub>2</sub> cell incubator for 3 days, changing half medium every 2 days. After 7 days, the cell suspension was transferred to a 15ml centrifuge tube, centrifuged, and recultured with neurobasal, 10%FBS, 1:50 B27(Thermo Fisher Scientific, A3582801), and 1:100 bFGF (Thermo Fisher Scientific, #RP-8626). One day later, the medium was changed to neurobasal (2%FBS, 1:50 B27, and 1:100 bFGF), culturing for 21 more days. The immunofluorescence technique was used with the neuron-specific marker (MAP2, #4542, Cell Signaling Technology, Boston, USA) to determine the purity of neurons.</p>
</sec>
<sec id="s4k">
<title>siRNA, shRNA, and adenovirus transfection</title>
<p>Notch1 siRNA and control siRNA were purchased from RiboBio (Guangzhou, China). HES1 shRNA and control shRNA were purchased from Qingke (Guangzhou, China). Green fluorescent protein-adenovirus (Ad-GFP) and Kallistatin-adenovirus (Ad-KAL) were provided by Dr. Jianxing Ma (University of Oklahoma Health Sciences Center). According to the manufacturer’s instructions, the transfections were performed at approximately 60% confluency using Lipofectamine®3000 transfection reagent (Invitrogen) or RNAiMAX. After 24 h, interference confirmation was conducted using real-time quantitative PCR (RT-qPCR) and Western blot.</p>
</sec>
<sec id="s4l">
<title>RNA isolation and quantitative RT-PCR</title>
<p>Total RNA extraction, reverse transcription of cDNA, and real-time quantitative PCR were performed as described previously <sup><xref ref-type="bibr" rid="c43">43</xref></sup>. BACE1 forward: GGAGCCCTTCTTTGACTCCC; BACE1 reverse: CAATGATCATGCTCCCTCCCA; ADAM9 forward: GGAAGGCTCCCTACTCTCTGA; ADAM9 reverse: CAATTCC-AAAACTGGCATTCTCC; ADAM10 forward: ATGGTGTTGCCGACAGTGTTA; ADAM10 reverse: GTTTGGCACGCTGGTGTTTTT; ADAM17 forward: GGAT-CTACAGTCTGCGACACA; ADAM17 reverse: TGAAAAGCGTTCGGTACTTGAT; β-actin forward: GCACTCTTCCAGCTTCCTT; β-actin reverse: GTTGGCGTACAG-GTCTTTGC.</p>
</sec>
<sec id="s4m">
<title>Western blot</title>
<p>Western blot was performed as described previously <sup><xref ref-type="bibr" rid="c40">40</xref>, <xref ref-type="bibr" rid="c43">43</xref></sup>. Equal amounts of protein were subjected to western blot analysis. Blots were probed with antibodies against Kallistatin (ab187656, Abcam, Cambridge, UK), Aβ (ab201060, Abcam, Cambridge, UK), Presenilin-1 (ab76083, Abcam, Cambridge, UK), BACE1 (#5606S, Cell Signaling Technology, Boston, USA), APP (#2452S, Cell Signaling Technology, Boston, USA), MAP2 (#4542, Cell Signaling Technology, Boston, USA), PPARγ (#2435, Cell Signaling Technology, Boston, USA), SP1 (#9389, Cell Signaling Technology, Boston, USA), YY1 (#46395, Cell Signaling Technology, Boston, USA), Notch1 (#3608, Cell Signaling Technology, Boston, USA), Hes1 (#11988, Cell Signaling Technology, Boston, USA), p-tau S202 (ab108387, Abcam, Cambridge, UK), p-tau T231(ab151559, Abcam, Cambridge, UK), p-tau S396 (ab109390, Abcam, Cambridge, UK), tau (ab75714, Abcam, Cambridge, UK), GSK3β(#70109S, Cell Signaling Technology, Boston, USA), p-GSK3β Ser9 (#9323, Cell Signaling Technology, Boston, USA), β-actin (A5441-2ml, Sigma, CA, USA), Caveolin-1(SZ02-01, Huabio, China), GAPDH (200306-7E4, Zen-bio, China), anti-Mouse (#PI200, Vector Laboratories, Burlingame, CA, USA), anti-Rabbit (#PI1000, Vector Laboratories, Burlingame, CA, USA). The signal intensity was quantified using ImageJ (NIH).</p>
</sec>
<sec id="s4n">
<title>Statistical Analysis</title>
<p>The results are expressed as mean ± SD. Student’s <italic>t</italic>-test was applied for comparisons of parametric data between two groups, and one-way ANOVA followed by LSD <italic>t</italic>-test was used to compare differences between more than two different groups (GraphPad Prism software). A <italic>P</italic> value less than 0.05 was considered statistical significance.</p>
</sec>
</sec>
</body>
<back>
<sec id="s13">
<table-wrap id="tbls1" orientation="portrait" position="float">
<label>Table. S1</label>
<caption><title>Clinical characteristic of AD patients</title></caption>
<graphic xlink:href="594915v2_tbls1.tif" mime-subtype="tiff" mimetype="image"/>
</table-wrap>
<table-wrap id="tbls2" orientation="portrait" position="float">
<label>Table. S2</label>
<caption><title>Clinical characteristic of AD patients with DM</title></caption>
<graphic xlink:href="594915v2_tbls2.tif" mime-subtype="tiff" mimetype="image"/>
<graphic xlink:href="594915v2_tbls2a.tif" mime-subtype="tiff" mimetype="image"/>
</table-wrap>
<fig id="figs1" position="float" orientation="portrait" fig-type="figure">
<label>Fig. S1</label>
<caption><p>(A-B) GAD disease enrichment analysis (A) and PFAM analysis (B) result. Differentially expressed genes in neurons were obtained from GSE161355, and GAD disease enrichment was analyzed on David database. (C-D) Western blot analysis of Kallistatin expression in aging model SAMP8 and corresponding control SAMR1 mice hippocampal tissue samples, then statistically analyzing the above results. β-Actin served as a loading control. Error bars represent the standard deviation (SD); one asterisks, <italic>p</italic> &lt; 0.05.</p></caption>
<graphic xlink:href="594915v2_figs1.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs2" position="float" orientation="portrait" fig-type="figure">
<label>Fig. S2</label>
<caption><p>(A) HT22 cells were infected with adenovirus to overexpress Kallistatin for 48h. Aβ42 concentration of supernate and cell lysate was quantified by ELISA. (B-C) Western blot analysis of Aβ protein level in HT22 cells infected with overexpressing Kallistatin adenovirus and control groups for 48h, then statistical analysis of Kallistatin protein levels. (D) BACE1 mRNA expression in hippocampal tissue. (E) α-secretases (ADAM9, ADAM10, ADAM17) mRNA expression in hippocampal tissue. (F) γ-secretase activity of each group’s hippocampal tissue was measured by ELISA. (G) Primary hippocampal neurons were identified with MAP2. Error bars represent the standard deviation (SD), one asterisk, <italic>p</italic> &lt; 0.05, two asterisks, <italic>p</italic> &lt; 0.01.</p></caption>
<graphic xlink:href="594915v2_figs2.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs3" position="float" orientation="portrait" fig-type="figure">
<label>Fig. S3</label>
<caption><p>(A) The relevant protein levels in HT22 cells infected with overexpressing Kallistatin adenovirus during Aβ generation were determined by western blot analysis. (B) Statistical analysis of BACE1 expression in HT22 cells. (C) β-secretase activity of HT22 cells infected with overexpressing Kallistatin adenovirus and control adenovirus was measured by ELISA. (D) Primary hippocampal neurons were infected with BACE1 siRNA for 72h. Western blot analysis of BACE1 protein levels. (E) HT22 cells were treated with PPARγ agonist rosiglitazone (10nM) for 12h, then infected with adenovirus to overexpress Kallistatin for 48h. Western blot analysis of Aβ and BACE1 protein levels. β-actin served as a loading control. Error bars represent the standard deviation (SD), two asterisks, <italic>p</italic> &lt; 0.01.</p></caption>
<graphic xlink:href="594915v2_figs3.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs4" position="float" orientation="portrait" fig-type="figure">
<label>Fig. S4</label>
<caption><p>(A-B) Western blot analysis of Notch1 protein level in primary hippocampal neurons and HT22 cells infected with overexpressing Kallistatin adenovirus and control groups. (C) HT22 cells were infected with overexpressing Kallistatin adenovirus for 48h, and Co-IP analysis was conducted to verify whether Kallistatin can bind to the Notch1 receptor. β-actin served as a loading control. (D) Primary hippocampal neurons were treated with Kallistatin protein for 72h, then IP analysis. (E) Primary hippocampal neurons were infected with Notch1 siRNA for 72h. Western blot analysis of BACE1 protein levels. (F) HT22 cells were infected with HES1 shRNA for 48h. Western blot analysis of HES1 protein levels.</p></caption>
<graphic xlink:href="594915v2_figs4.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs5" position="float" orientation="portrait" fig-type="figure">
<label>Fig. S5</label>
<caption><p>(A) Western blot analysis of GSK-3β, p-GSK-3β, tau, p-tau(Ser9, T231, S396) in HT22 cells infected with overexpressing Kallistatin adenovirus and control groups. (B) Western blot analysis of GSK-3β, p-GSK-3β, p-tau(Ser9, T231, S396) in HT22 cells infected with overexpressing Kallistatin adenovirus and control groups for 24h, then treated with LiCl(10 mM) for 24h. (C) Simplified model depicting the pathway of Aβ regulated by Kallistatin.</p></caption>
<graphic xlink:href="594915v2_figs5.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<sec id="s9" sec-type="data-availability">
<title>Availability of data and materials</title>
<p>All the data supporting the conclusions of the current study are presented in the figures and they are available from the corresponding authors upon reasonable request. There are no restrictions on data availability. Source data are provided with this paper.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>We are thankful to Zhongshan City People’s Hospital, Zhongshan Third People’s Hospital, Guangdong Provincial People’s Hospital, and Sun Yat-sen Memorial Hospital for kindly providing serum samples for the analyses of this manuscript. We thank Professor Boxing Li for his valuable advice on our study.</p>
</ack>
<sec id="d1e1662" sec-type="additional-information">
<title>Additional information</title>
<sec id="s11">
<title>Funding</title>
<p>This study was supported by The National Natural Science Foundation of China (Grants 82070888, 82070882, 82100917, 82273116, 82203661, 81901557, 81870869, and 32071101); Guangdong Natural Science Fund (Grant 2022A1515012423, 2021A1515010434, 2023A1515010316, and 2023A1515010214); Key Sci-Tech Research Project of Guangzhou Municipality, China (Grants 202201010820, 202102020955); Key Project of Nature Science Foundation of Guangdong Province, China (Grant 2019B1515120077); National Key R&amp;D Program of China (Grant 2018YFA0800403); Guangdong Special Support Program for Young Top Scientist (Grant 201629046); China Postdoctoral Science Foundation (Grant 2021M703679, 2022M713594, BX20220360); Health Commission of Guangdong Province (Grants A2022161); Guangzhou Municipal Science and Technology Bureau (Grants SL2022A04J01575); Guangdong Key Project in “Development of new tools for diagnosis and treatment of Autism” (2018B030335001), Research and Development Plan of Key Areas of Guangzhou Science and Technology Bureau (2020070030001), Open Research Funds of State Key Laboratory of Ophthalmology (2020KF03); Guangzhou Key Laboratory for Metabolic Diseases(202102100004); The Science and Technology Planning Project of Guangdong Province 2023B1212060018.</p>
</sec>
<sec id="s12">
<title>Authors’ contributions</title>
<p>G. Gao, X Yang, B Jiang, and P Jiang were involved in the concept and design of the study. W. Qi, Y. Long, Z. Li, Z. Zhao J. Shi, D Zhu, Z Zhao, W. Xie, L. Wang, T Zhou, Mingting Liang were responsible for conducting the experiments. W. Qi, Y. Long and T Zhou drafted the manuscript and G. Gao revised the manuscript. P Jiang, Y. Long and Z. Li were responsible for data analysis. All authors contributed to the interpretation of data and provided revisions to the manuscript. G. Gao will act as guarantor for the study. All authors read and approved the final manuscript. W. Qi, Y. Long and Z. Li contributed equally to this study.</p>
</sec>
<glossary>
<title>List of abbreviations</title>
<def-list>
<def-item>
<term>Aβ</term>
<def><p>amyloid β</p></def>
</def-item>
<def-item>
<term>p-tau</term>
<def><p>hyperphosphorylated tau</p></def>
</def-item>
<def-item>
<term>AD</term>
<def><p>Alzheimer’s disease</p></def>
</def-item>
<def-item>
<term>T2DM</term>
<def><p>type 2 diabetes mellitus</p></def>
</def-item>
<def-item>
<term>FBG</term>
<def><p>fasting blood glucose</p></def>
</def-item>
<def-item>
<term>TG</term>
<def><p>triglyceride</p></def>
</def-item>
<def-item>
<term>KAL-TG</term>
<def><p>Kallistatin-transgenic</p></def>
</def-item>
<def-item>
<term>WT</term>
<def><p>wild type mice</p></def>
</def-item>
<def-item>
<term>APP</term>
<def><p>amyloid precursor protein</p></def>
</def-item>
<def-item>
<term>BACE1</term>
<def><p>β-site APP cleaving enzyme 1</p></def>
</def-item>
<def-item>
<term>BMI</term>
<def><p>body mass index</p></def>
</def-item>
<def-item>
<term>ICD-10</term>
<def><p>The International Statistical Classification of Diseases and Related Health Problems 10th Revision</p></def>
</def-item>
<def-item>
<term>NINCDS-ADRDA</term>
<def><p>the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association</p></def>
</def-item>
<def-item>
<term>MMSE</term>
<def><p>mini-Mental State Examination</p></def>
</def-item>
<def-item>
<term>KAL-TG-RSG</term>
<def><p>rosiglitazone-treated group</p></def>
</def-item>
<def-item>
<term>KAL-TG-Feno</term>
<def><p>fenofibrate-treated group</p></def>
</def-item>
<def-item>
<term>MWM</term>
<def><p>morris water maze</p></def>
</def-item>
<def-item>
<term>RT-qPCR</term>
<def><p>real-time quantitative PCR</p></def>
</def-item>
</def-list>
</glossary>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grundke-Iqbal</surname> <given-names>I</given-names></string-name>, <string-name><surname>Iqbal</surname> <given-names>K</given-names></string-name>, <string-name><surname>Tung</surname> <given-names>YC</given-names></string-name>, <string-name><surname>Quinlan</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wisniewski</surname> <given-names>HM</given-names></string-name>, <string-name><surname>Binder</surname> <given-names>LI</given-names></string-name></person-group>. <article-title>Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source> <year>1986</year>, <volume>83</volume>(<issue>13</issue>): <fpage>4913</fpage>–<lpage>4917</lpage>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haass</surname> <given-names>C</given-names></string-name>, <string-name><surname>Selkoe</surname> <given-names>DJ</given-names></string-name></person-group>. <article-title>Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide</article-title>. <source>Nature Reviews Molecular Cell Biology</source> <year>2007</year>, <volume>8</volume>(<issue>2</issue>): <fpage>101</fpage>–<lpage>112</lpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Holtzman</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Morris</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Goate</surname> <given-names>AM</given-names></string-name></person-group>. <article-title>Alzheimer’s Disease: The Challenge of the Second Century</article-title>. <source>Science Translational Medicine</source> <year>2011</year>, <volume>3</volume>(<issue>77</issue>).</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leng</surname> <given-names>F</given-names></string-name>, <string-name><surname>Edison</surname> <given-names>P</given-names></string-name></person-group>. <article-title>Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?</article-title> <source>Nature Reviews Neurology</source> <year>2021</year>, <volume>17</volume>(<issue>3</issue>): <fpage>157</fpage>–<lpage>172</lpage>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Strooper</surname> <given-names>B</given-names></string-name>, <string-name><surname>Karran</surname> <given-names>E</given-names></string-name></person-group>. <article-title>The Cellular Phase of Alzheimer’s Disease</article-title>. <source>Cell</source> <year>2016</year>, <volume>164</volume>(<issue>4</issue>): <fpage>603</fpage>–<lpage>615</lpage>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tomita</surname> <given-names>T</given-names></string-name></person-group>. <article-title>Molecular mechanism of intramembrane proteolysis by gamma-secretase</article-title>. <source>Journal of Biochemistry</source> <year>2014</year>, <volume>156</volume>(<issue>4</issue>): <fpage>195</fpage>–<lpage>201</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>LaFerla</surname> <given-names>FM</given-names></string-name>, <string-name><surname>Green</surname> <given-names>KN</given-names></string-name>, <string-name><surname>Oddo</surname> <given-names>S</given-names></string-name></person-group>. <article-title>Intracellular amyloid-beta in Alzheimer’s disease</article-title>. <source>Nature Reviews Neuroscience</source> <year>2007</year>, <volume>8</volume>(<issue>7</issue>): <fpage>499</fpage>–<lpage>509</lpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Das</surname> <given-names>B</given-names></string-name>, <string-name><surname>Yan</surname> <given-names>R</given-names></string-name></person-group>. <article-title>A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment</article-title>. <source>Cns Drugs</source> <year>2019</year>, <volume>33</volume>(<issue>3</issue>): <fpage>251</fpage>–<lpage>263</lpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Crunkhorn</surname>, <given-names>Sarah</given-names></string-name></person-group>. <article-title>Alzheimer disease: BACE1 inhibitor reduces β-amyloid production in humans</article-title>. <source>Nature Reviews Drug Discovery</source> <year>2016</year>, <volume>16</volume>(<issue>1</issue>): <fpage>18</fpage>–<lpage>18</lpage>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yan</surname> <given-names>R</given-names></string-name>, <string-name><surname>Vassar</surname> <given-names>R</given-names></string-name></person-group>. <article-title>Targeting the β secretase BACE1 for Alzheimer’s disease therapy</article-title>. <source>Lancet Neurology</source> <year>2014</year>, <volume>13</volume>(<issue>3</issue>): <fpage>319</fpage>–<lpage>329</lpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Mandelkow</surname> <given-names>E.</given-names></string-name></person-group> <article-title>Tau in physiology and pathology</article-title>. <source>Nature reviews Neuroscience</source> <year>2016</year>, <volume>17</volume>(<issue>1</issue>): <fpage>5</fpage>–<lpage>21</lpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hausrat</surname> <given-names>TJ</given-names></string-name>, <string-name><surname>Janiesch</surname> <given-names>PC</given-names></string-name>, <string-name><surname>Breiden</surname> <given-names>P</given-names></string-name>, <string-name><surname>Lutz</surname> <given-names>D</given-names></string-name>, <string-name><surname>Hoffmeister-Ullerich</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hermans-Borgmeyer</surname> <given-names>I</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Disruption of tubulin-alpha4a polyglutamylation prevents aggregation of hyper-phosphorylated tau and microglia activation in mice</article-title>. <source>Nature communications</source> <year>2022</year>, <volume>13</volume>(<issue>1</issue>): <fpage>4192</fpage>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Braak</surname> <given-names>E</given-names></string-name>, <string-name><surname>Braak</surname> <given-names>H</given-names></string-name>, <string-name><surname>Mandelkow</surname> <given-names>EM</given-names></string-name></person-group>. <article-title>A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads</article-title>. <source>Acta neuropathologica</source> <year>1994</year>, <volume>87</volume>(<issue>6</issue>): <fpage>554</fpage>–<lpage>567</lpage>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boonen</surname> <given-names>RA</given-names></string-name>, <string-name><surname>van Tijn</surname> <given-names>P</given-names></string-name>, <string-name><surname>Zivkovic</surname> <given-names>D</given-names></string-name></person-group>. <article-title>Wnt signaling in Alzheimer’s disease: up or down, that is the question</article-title>. <source>Ageing Res Rev</source> <year>2009</year>, <volume>8</volume>(<issue>2</issue>): <fpage>71</fpage>–<lpage>82</lpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Biessels</surname> <given-names>GJ</given-names></string-name>, <string-name><surname>Despa</surname> <given-names>F</given-names></string-name></person-group>. <article-title>Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications</article-title>. <source>Nature Reviews Endocrinology</source> <year>2018</year>, <volume>14</volume>(<issue>10</issue>): <fpage>591</fpage>–<lpage>604</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname> <given-names>W</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>E</given-names></string-name>, <string-name><surname>Gao</surname> <given-names>S</given-names></string-name></person-group>. <article-title>Type 1 Diabetes Mellitus and Cognitive Impairments: A Systematic Review</article-title>. <source>Journal of Alzheimers Disease</source> <year>2017</year>, <volume>57</volume>(<issue>1</issue>): <fpage>29</fpage>–<lpage>36</lpage>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Cardoso</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Correia</surname> <given-names>SC</given-names></string-name>, <string-name><surname>Carvalho</surname> <given-names>C</given-names></string-name>, <string-name><surname>Moreira</surname> <given-names>PI.</given-names></string-name></person-group> <chapter-title>Mitochondria in Alzheimer’s Disease and Diabetes-Associated Neurodegeneration: License to Heal!</chapter-title> In: <person-group person-group-type="editor"><string-name><surname>Singh</surname> <given-names>H</given-names></string-name>, <string-name><surname>Sheu</surname> <given-names>SS</given-names></string-name></person-group> (eds). <source>Pharmacology of Mitochondria</source>, <publisher-name>Springer</publisher-name>, vol. <volume>240</volume>, <year>2017</year>, pp <fpage>281</fpage>–<lpage>308</lpage>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schipper</surname> <given-names>HM</given-names></string-name></person-group>. <article-title>Apolipoprotein E: Implications for AD neurobiology, epidemiology and risk assessment</article-title>. <source>Neurobiology of Aging</source> <year>2011</year>, <volume>32</volume>(<issue>5</issue>): <fpage>778</fpage>–<lpage>790</lpage>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Folch</surname> <given-names>J</given-names></string-name>, <string-name><surname>Patraca</surname> <given-names>I</given-names></string-name>, <string-name><surname>Martinez</surname> <given-names>N</given-names></string-name>, <string-name><surname>Pedros</surname> <given-names>I</given-names></string-name>, <string-name><surname>Petrov</surname> <given-names>D</given-names></string-name>, <string-name><surname>Ettcheto</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>The role of leptin in the sporadic form of Alzheimer’s disease. Interactions with the adipokines amylin, ghrelin and the pituitary hormone prolactin</article-title>. <source>Life Sciences</source> <year>2015</year>, <volume>140</volume>: <fpage>19</fpage>–<lpage>28</lpage>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Association As</collab></person-group>. <article-title>2016 Alzheimer’s disease facts and figures</article-title>. <source>Alzheimer’s &amp; Dementia</source> <year>2016</year>, <volume>12</volume>(<issue>4</issue>): <fpage>459</fpage>–<lpage>509</lpage>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baglietto-Vargas</surname> <given-names>D</given-names></string-name>, <string-name><surname>Shi</surname> <given-names>J</given-names></string-name>, <string-name><surname>Yaeger</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Ager</surname> <given-names>R</given-names></string-name>, <string-name><surname>LaFerla</surname> <given-names>FM.</given-names></string-name></person-group> <article-title>Diabetes and Alzheimer’s disease crosstalk</article-title>. <source>Neuroscience &amp; Biobehavioral Reviews</source> <year>2016</year>, <volume>64</volume>: <fpage>272</fpage>–<lpage>287</lpage>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kandimalla</surname> <given-names>R</given-names></string-name>, <string-name><surname>Thirumala</surname> <given-names>V</given-names></string-name>, <string-name><surname>Reddy</surname> <given-names>PH</given-names></string-name></person-group>. <article-title>Is Alzheimer’s disease a Type 3 Diabetes?</article-title> <source>A critical appraisal. Biochimica Et Biophysica Acta-Molecular Basis of Disease</source> <year>2017</year>, <volume>1863</volume>(<issue>5</issue>): <fpage>1078</fpage>–<lpage>1089</lpage>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>N-q</given-names></string-name>, <string-name><surname>Yan</surname> <given-names>F</given-names></string-name>, <string-name><surname>Jin</surname> <given-names>H</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>S-y</given-names></string-name>, <string-name><surname>Shi</surname> <given-names>J-s</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Diabetes mellitus and Alzheimer’s disease: GSK-3 beta as a potential link</article-title>. <source>Behavioural Brain Research</source> <year>2018</year>, <volume>339</volume>: <fpage>57</fpage>–<lpage>65</lpage>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Steen</surname> <given-names>E</given-names></string-name>, <string-name><surname>Terry</surname> <given-names>BM</given-names></string-name>, <string-name><surname>Rivera</surname> <given-names>EJ</given-names></string-name>, <string-name><surname>Cannon</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Neely</surname> <given-names>TR</given-names></string-name>, <string-name><surname>Tavares</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease - is this type 3 diabetes?</article-title> <source>Journal of Alzheimers Disease</source> <year>2005</year>, <volume>7</volume>(<issue>1</issue>): <fpage>63</fpage>–<lpage>80</lpage>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Candasamy</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mohamed Elhassan</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Kumar Bhattamisra</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hua</surname> <given-names>WY</given-names></string-name>, <string-name><surname>Sern</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Binti Busthamin</surname> <given-names>NA</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Type 3 diabetes (Alzheimer’s disease): new insight for promising therapeutic avenues</article-title>. <source>Panminerva Medica</source> <year>2020</year>, <volume>62</volume>(<issue>3</issue>): <fpage>155</fpage>–<lpage>163</lpage>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koekkoek</surname> <given-names>PS</given-names></string-name>, <string-name><surname>Kappelle</surname> <given-names>LJ</given-names></string-name>, <string-name><surname>van den Berg</surname> <given-names>E</given-names></string-name>, <string-name><surname>Rutten</surname> <given-names>GE</given-names></string-name>, <string-name><surname>Biessels</surname> <given-names>GJ.</given-names></string-name></person-group> <article-title>Cognitive function in patients with diabetes mellitus: guidance for daily care</article-title>. <source>The Lancet Neurology</source> <year>2015</year>, <volume>14</volume>(<issue>3</issue>): <fpage>329</fpage>–<lpage>340</lpage>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hildreth</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Van Pelt</surname> <given-names>RE</given-names></string-name>, <string-name><surname>Schwartz</surname> <given-names>RS.</given-names></string-name></person-group> <article-title>Obesity, insulin resistance, and Alzheimer’s disease</article-title>. <source>Obesity (Silver Spring, Md)</source> <year>2012</year>, <volume>20</volume>(<issue>8</issue>): <fpage>1549</fpage>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anjum</surname> <given-names>I</given-names></string-name>, <string-name><surname>Fayyaz</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wajid</surname> <given-names>A</given-names></string-name>, <string-name><surname>Sohail</surname> <given-names>W</given-names></string-name>, <string-name><surname>Ali</surname> <given-names>A</given-names></string-name></person-group>. <article-title>Does obesity increase the risk of dementia: a literature review</article-title>. <source>Cureus</source> <year>2018</year>, <volume>10</volume>(<issue>5</issue>).</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ma</surname> <given-names>C</given-names></string-name>, <string-name><surname>Luo</surname> <given-names>C</given-names></string-name>, <string-name><surname>Yin</surname> <given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Xiong</surname> <given-names>W</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Kallistatin inhibits lymphangiogenesis and lymphatic metastasis of gastric cancer by downregulating VEGF-C expression and secretion</article-title>. <source>Gastric Cancer</source> <year>2018</year>, <volume>21</volume>(<issue>4</issue>): <fpage>617</fpage>–<lpage>631</lpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>He</surname> <given-names>X</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>R</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Shan</surname> <given-names>C</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Diabetes-induced upregulation of Kallistatin levels exacerbates diabetic nephropathy via RAS activation</article-title>. <source>Faseb Journal</source> <year>2020</year>, <volume>34</volume>(<issue>6</issue>): <fpage>8428</fpage>–<lpage>8441</lpage>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ma</surname> <given-names>C</given-names></string-name>, <string-name><surname>Yin</surname> <given-names>H</given-names></string-name>, <string-name><surname>Zhong</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Luo</surname> <given-names>C</given-names></string-name>, <string-name><surname>Che</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Kallistatin exerts anti-lymphangiogenic effects by inhibiting lymphatic endothelial cell proliferation, migration and tube formation</article-title>. <source>International Journal of Oncology</source> <year>2017</year>, <volume>50</volume>(<issue>6</issue>): <fpage>2000</fpage>–<lpage>2010</lpage>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>El-Asrar</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Andrawes</surname> <given-names>NG</given-names></string-name>, <string-name><surname>Ismail</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Salem</surname> <given-names>SMH</given-names></string-name></person-group>. <article-title>Kallistatin as a marker of microvascular complications in children and adolescents with type 1 diabetes mellitus: Relation to carotid intima media thickness</article-title>. <source>Vascular Medicine</source> <year>2015</year>, <volume>20</volume>(<issue>6</issue>): <fpage>509</fpage>–<lpage>517</lpage>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gateva</surname> <given-names>A</given-names></string-name>, <string-name><surname>Assyov</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Velikova</surname> <given-names>T</given-names></string-name>, <string-name><surname>Kamenov</surname> <given-names>Z</given-names></string-name></person-group>. <article-title>Increased Kallistatin levels in patients with obesity and prediabetes compared to normal glucose tolerance</article-title>. <source>Endocrine Research</source> <year>2017</year>, <volume>42</volume>(<issue>2</issue>): <fpage>163</fpage>–<lpage>168</lpage>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Campbell</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Kladis</surname> <given-names>A</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Jenkins</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Prior</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Yii</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Increased tissue kallikrein levels in type 2 diabetes</article-title>. <source>Diabetologia</source> <year>2010</year>, <volume>53</volume>(<issue>4</issue>): <fpage>779</fpage>–<lpage>785</lpage>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nowicki</surname> <given-names>GJ</given-names></string-name>, <string-name><surname>Ślusarska</surname> <given-names>B</given-names></string-name>, <string-name><surname>Polak</surname> <given-names>M</given-names></string-name>, <string-name><surname>Naylor</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kocki</surname> <given-names>T.</given-names></string-name></person-group> <article-title>Relationship between Serum Kallistatin and Afamin and Anthropometric Factors Associated with Obesity and of Being Overweight in Patients after Myocardial Infarction and without Myocardial Infarction</article-title>. <source>Journal of clinical medicine</source> <year>2021</year>, <volume>10</volume>(<issue>24</issue>).</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hong</surname> <given-names>S</given-names></string-name>, <string-name><surname>Han</surname> <given-names>K</given-names></string-name>, <string-name><surname>Park</surname> <given-names>CY</given-names></string-name></person-group>. <article-title>The insulin resistance by triglyceride glucose index and risk for dementia: population-based study</article-title>. <source>Alzheimer’s research &amp; therapy</source> <year>2021</year>, <volume>13</volume>(<issue>1</issue>): <fpage>9</fpage>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feng</surname> <given-names>J</given-names></string-name>, <string-name><surname>Dong</surname> <given-names>C</given-names></string-name>, <string-name><surname>Long</surname> <given-names>YL</given-names></string-name>, <string-name><surname>Mai</surname> <given-names>LF</given-names></string-name>, <string-name><surname>Ren</surname> <given-names>M</given-names></string-name>, <string-name><surname>Li</surname> <given-names>LY</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Elevated Kallikrein-binding protein in diabetes impairs wound healing through inducing macrophage M1 polarization</article-title>. <source>Cell Communication and Signaling</source> <year>2019</year>, <volume>17</volume>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Long</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Xie</surname> <given-names>W</given-names></string-name>, <string-name><surname>Shi</surname> <given-names>J</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>F</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Kallistatin leads to cognition impairment via downregulating glutamine synthetase</article-title>. <source>Pharmacol Res</source> <year>2024</year>, <volume>202</volume>: <fpage>107145</fpage>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McBride</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Jenkins</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>XC</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>B</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>K</given-names></string-name>, <string-name><surname>Berry</surname> <given-names>WL</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Elevated Circulation Levels of an Antiangiogenic SERPIN in Patients with Diabetic Microvascular Complications Impair Wound Healing through Suppression of Wnt Signaling</article-title>. <source>Journal of Investigative Dermatology</source> <year>2014</year>, <volume>134</volume>(<issue>6</issue>): <fpage>1725</fpage>–<lpage>1734</lpage>.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname> <given-names>M</given-names></string-name>, <string-name><surname>Qi</surname> <given-names>WW</given-names></string-name>, <string-name><surname>Fang</surname> <given-names>SH</given-names></string-name>, <string-name><surname>Jiang</surname> <given-names>P</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>C</given-names></string-name>, <string-name><surname>Mo</surname> <given-names>YS</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Pigment Epithelium-Derived Factor Plays a Role in Alzheimer’s Disease by Negatively Regulating A beta 42</article-title>. <source>Neurotherapeutics</source> <year>2018</year>, <volume>15</volume>(<issue>3</issue>): <fpage>728</fpage>–<lpage>741</lpage>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guo</surname> <given-names>D</given-names></string-name>, <string-name><surname>Peng</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Sun</surname> <given-names>X</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Liang</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Autism-like social deficit generated by Dock4 deficiency is rescued by restoration of Rac1 activity and NMDA receptor function</article-title>. <source>Mol Psychiatry</source> <year>2021</year>, <volume>26</volume>(<issue>5</issue>): <fpage>1505</fpage>–<lpage>1519</lpage>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname> <given-names>C</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>L</given-names></string-name>, <string-name><surname>Yu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Gao</surname> <given-names>T</given-names></string-name>, <string-name><surname>Feng</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>The contrary intracellular and extracellular functions of PEDF in HCC development</article-title>. <source>Cell Death &amp; Disease</source> <year>2019</year>, <volume>10</volume>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jiang</surname> <given-names>P</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>M</given-names></string-name>, <string-name><surname>Qi</surname> <given-names>WW</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>FH</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>TY</given-names></string-name>, <string-name><surname>Gao</surname> <given-names>TX</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>FUBP1 promotes neuroblastoma proliferation via enhancing glycolysis-a new possible marker of malignancy for neuroblastoma</article-title>. <source>Journal of Experimental &amp; Clinical Cancer Research</source> <year>2019</year>, <volume>38</volume>(<issue>1</issue>).</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feng</surname> <given-names>J</given-names></string-name>, <string-name><surname>Dong</surname> <given-names>C</given-names></string-name>, <string-name><surname>Long</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Mai</surname> <given-names>L</given-names></string-name>, <string-name><surname>Ren</surname> <given-names>M</given-names></string-name>, <string-name><surname>Li</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Elevated Kallikrein-binding protein in diabetes impairs wound healing through inducing macrophage M1 polarization</article-title>. <source>Cell Communication and Signaling</source> <year>2019</year>, <volume>17</volume>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Strooper</surname> <given-names>B</given-names></string-name>, <string-name><surname>Annaert</surname> <given-names>W</given-names></string-name></person-group>. <article-title>Proteolytic processing and cell biological functions of the amyloid precursor protein</article-title>. <source>Journal of Cell Science</source> <year>2000</year>, <volume>113</volume>(<issue>11</issue>): <fpage>1857</fpage>–<lpage>1870</lpage>.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>LaFerla</surname> <given-names>FM</given-names></string-name>, <string-name><surname>Oddo</surname> <given-names>S</given-names></string-name></person-group>. <article-title>Alzheimer’s disease: A beta, tau and synaptic dysfunction</article-title>. <source>Trends in Molecular Medicine</source> <year>2005</year>, <volume>11</volume>(<issue>4</issue>): <fpage>170</fpage>–<lpage>176</lpage>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scheuner</surname> <given-names>D</given-names></string-name>, <string-name><surname>Eckman</surname> <given-names>C</given-names></string-name>, <string-name><surname>Jensen</surname> <given-names>M</given-names></string-name>, <string-name><surname>Song</surname> <given-names>X</given-names></string-name>, <string-name><surname>Citron</surname> <given-names>M</given-names></string-name>, <string-name><surname>Suzuki</surname> <given-names>N</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease</article-title>. <source>Nature Medicine</source> <year>1996</year>, <volume>2</volume>(<issue>8</issue>): <fpage>864</fpage>–<lpage>870</lpage>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Christensen</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>WH</given-names></string-name>, <string-name><surname>Qing</surname> <given-names>H</given-names></string-name>, <string-name><surname>Lehman</surname> <given-names>A</given-names></string-name>, <string-name><surname>Philipsen</surname> <given-names>S</given-names></string-name>, <string-name><surname>Song</surname> <given-names>WH</given-names></string-name></person-group>. <article-title>Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1</article-title>. <source>Molecular and Cellular Biology</source> <year>2004</year>, <volume>24</volume>(<issue>2</issue>): <fpage>865</fpage>–<lpage>874</lpage>.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lin</surname> <given-names>N</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>L-m</given-names></string-name>, <string-name><surname>Pan</surname> <given-names>X-d</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>Y-g</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Shi</surname> <given-names>Y-q</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Tripchlorolide Attenuates beta-amyloid Generation via Suppressing PPAR gamma-Regulated BACE1 Activity in N2a/APP695 Cells</article-title>. <source>Molecular Neurobiology</source> <year>2016</year>, <volume>53</volume>(<issue>9</issue>): <fpage>6397</fpage>–<lpage>6406</lpage>.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nowak</surname> <given-names>K</given-names></string-name>, <string-name><surname>Lange-Dohna</surname> <given-names>C</given-names></string-name>, <string-name><surname>Zeitschel</surname> <given-names>U</given-names></string-name>, <string-name><surname>Gunther</surname> <given-names>A</given-names></string-name>, <string-name><surname>Luscher</surname> <given-names>B</given-names></string-name>, <string-name><surname>Robitzki</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>The transcription factor Yin Yang 1 is an activator of BACE1 expression</article-title>. <source>Journal of Neurochemistry</source> <year>2006</year>, <volume>96</volume>(<issue>6</issue>): <fpage>1696</fpage>–<lpage>1707</lpage>.</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maniati</surname> <given-names>E</given-names></string-name>, <string-name><surname>Bossard</surname> <given-names>M</given-names></string-name>, <string-name><surname>Cook</surname> <given-names>N</given-names></string-name>, <string-name><surname>Candido</surname> <given-names>JB</given-names></string-name>, <string-name><surname>Emami-Shahri</surname> <given-names>N</given-names></string-name>, <string-name><surname>Nedospasov</surname> <given-names>SA</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice</article-title>. <source>The Journal of clinical investigation</source> <year>2011</year>, <volume>121</volume>(<issue>12</issue>): <fpage>4685</fpage>–<lpage>4699</lpage>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Herzig</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hedrick</surname> <given-names>S</given-names></string-name>, <string-name><surname>Morantte</surname> <given-names>I</given-names></string-name>, <string-name><surname>Koo</surname> <given-names>SH</given-names></string-name>, <string-name><surname>Galimi</surname> <given-names>F</given-names></string-name>, <string-name><surname>Montminy</surname> <given-names>M</given-names></string-name></person-group>. <article-title>CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-gamma</article-title>. <source>Nature</source> <year>2003</year>, <volume>426</volume>(<issue>6963</issue>): <fpage>190</fpage>–<lpage>193</lpage>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kanno</surname> <given-names>T</given-names></string-name>, <string-name><surname>Tsuchiya</surname> <given-names>A</given-names></string-name>, <string-name><surname>Tanaka</surname> <given-names>A</given-names></string-name>, <string-name><surname>Nishizaki</surname> <given-names>T</given-names></string-name></person-group>. <article-title>Combination of PKCε Activation and PTP1B Inhibition Effectively Suppresses Aβ-Induced GSK-3β Activation and Tau Phosphorylation</article-title>. <source>Mol Neurobiol</source> <year>2016</year>, <volume>53</volume>(<issue>7</issue>): <fpage>4787</fpage>–<lpage>4797</lpage>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Piao</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>SH</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>H</given-names></string-name>, <string-name><surname>Yum</surname> <given-names>S</given-names></string-name>, <string-name><surname>Stamos</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Direct inhibition of GSK3beta by the phosphorylated cytoplasmic domain of LRP6 in Wnt/beta-catenin signaling</article-title>. <source>PLoS One</source> <year>2008</year>, <volume>3</volume>(<issue>12</issue>): <fpage>e4046</fpage>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>B</given-names></string-name>, <string-name><surname>McBride</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>K</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>K</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Antiangiogenic and antineuroinflammatory effects of Kallistatin through interactions with the canonical Wnt pathway</article-title>. <source>Diabetes</source> <year>2013</year>, <volume>62</volume>(<issue>12</issue>): <fpage>4228</fpage>–<lpage>4238</lpage>.</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kubis-Kubiak</surname> <given-names>A</given-names></string-name>, <string-name><surname>Wiatrak</surname> <given-names>B</given-names></string-name>, <string-name><surname>Piwowar</surname> <given-names>A</given-names></string-name></person-group>. <article-title>Hyper-glycemia and insulinemia induce morphological changes and modulate secretion of S100B, S100A8, amyloid β 1-40 and amyloid β 1-42, in a model of human dopaminergic neurons</article-title>. <source>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</source> <year>2022</year>, <volume>156</volume>: <fpage>113869</fpage>.</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rivas-Domínguez</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mohamed-Mohamed</surname> <given-names>H</given-names></string-name>, <string-name><surname>Jimenez-Palomares</surname> <given-names>M</given-names></string-name>, <string-name><surname>García-Morales</surname> <given-names>V</given-names></string-name>, <string-name><surname>Martinez-Lopez</surname> <given-names>L</given-names></string-name>, <string-name><surname>Orta</surname> <given-names>ML</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Metabolic Disturbance of High-Saturated Fatty Acid Diet in Cognitive Preservation</article-title>. <source>International journal of molecular sciences</source> <year>2023</year>, <volume>24</volume>(<issue>9</issue>).</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Suzanne</surname> <given-names>M</given-names></string-name></person-group>. <article-title>Type 3 diabetes is sporadic Alzheimer-s disease: mini-review</article-title>. <source>European Neuropsychopharmacology</source> <year>2014</year>, <volume>24</volume>(<issue>12</issue>): <fpage>1954</fpage>–<lpage>1960</lpage>.</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Biessels</surname> <given-names>GJ</given-names></string-name>, <string-name><surname>Reagan</surname> <given-names>LP</given-names></string-name></person-group>. <article-title>Hippocampal insulin resistance and cognitive dysfunction</article-title>. <source>Nature reviews Neuroscience</source> <year>2015</year>, <volume>16</volume>(<issue>11</issue>): <fpage>660</fpage>–<lpage>671</lpage>.</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname> <given-names>W</given-names></string-name>, <string-name><surname>Caracciolo</surname> <given-names>B</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>HX</given-names></string-name>, <string-name><surname>Winblad</surname> <given-names>B</given-names></string-name>, <string-name><surname>Bäckman</surname> <given-names>L</given-names></string-name>, <string-name><surname>Qiu</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Accelerated progression from mild cognitive impairment to dementia in people with diabetes</article-title>. <source>Diabetes</source> <year>2010</year>, <volume>59</volume>(<issue>11</issue>): <fpage>2928</fpage>–<lpage>2935</lpage>.</mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Selkoe</surname> <given-names>DJ.</given-names></string-name></person-group> <article-title>Toward a comprehensive theory for Alzheimer’s disease - Hypothesis: Alzheimer’s disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein</article-title>. <source>Alzheimers Disease: A Compendium of Current Theories</source>, vol. <volume>924</volume>, <year>2000</year>, pp <fpage>17</fpage>–<lpage>25</lpage>.</mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thijs</surname> <given-names>V</given-names></string-name>, <string-name><surname>Robberecht</surname> <given-names>W</given-names></string-name>, <string-name><surname>De Vos</surname> <given-names>R</given-names></string-name>, <string-name><surname>Sciot</surname> <given-names>R.</given-names></string-name></person-group> <article-title>Coexistence of CADASIL and Alzheimer’s disease</article-title>. <source>Journal of Neurology Neurosurgery and Psychiatry</source> <year>2003</year>, <volume>74</volume>(<issue>6</issue>): <fpage>790</fpage>–<lpage>792</lpage>.</mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brai</surname> <given-names>E</given-names></string-name>, <string-name><surname>Raio</surname> <given-names>NA</given-names></string-name>, <string-name><surname>Alberi</surname> <given-names>L</given-names></string-name></person-group>. <article-title>Notch1 hallmarks fibrillary depositions in sporadic Alzheimer’s disease</article-title>. <source>Acta Neuropathologica Communications</source> <year>2016</year>, <volume>4</volume>.</mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname> <given-names>B</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>D</given-names></string-name>, <string-name><surname>Xiong</surname> <given-names>T</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Jing</surname> <given-names>X</given-names></string-name>, <string-name><surname>Du</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Inhibition of Notch Signaling Promotes the Differentiation of Epicardial Progenitor Cells into Adipocytes</article-title>. <source>Stem Cells Int</source> <year>2021</year>, <volume>2021</volume>: <fpage>8859071</fpage>.</mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>D’Souza</surname> <given-names>B</given-names></string-name>, <string-name><surname>Meloty-Kapella</surname> <given-names>L</given-names></string-name>, <string-name><surname>Weinmaster</surname> <given-names>G.</given-names></string-name></person-group> <article-title>Canonical and non-canonical notch ligands</article-title>. <source>Notch Signaling</source>, vol. <volume>92</volume>, <year>2010</year>, pp <fpage>73</fpage>–<lpage>129</lpage>.</mixed-citation></ref>
<ref id="c66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Salloway</surname> <given-names>S</given-names></string-name>, <string-name><surname>Sperling</surname> <given-names>R</given-names></string-name>, <string-name><surname>Fox</surname> <given-names>NC</given-names></string-name>, <string-name><surname>Blennow</surname> <given-names>K</given-names></string-name>, <string-name><surname>Klunk</surname> <given-names>W</given-names></string-name>, <string-name><surname>Raskind</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease</article-title>. <source>New England Journal of Medicine</source> <year>2014</year>, <volume>370</volume>(<issue>4</issue>): <fpage>322</fpage>–<lpage>333</lpage>.</mixed-citation></ref>
<ref id="c67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ostrowitzki</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lasser</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Dorflinger</surname> <given-names>E</given-names></string-name>, <string-name><surname>Scheltens</surname> <given-names>P</given-names></string-name>, <string-name><surname>Barkhof</surname> <given-names>F</given-names></string-name>, <string-name><surname>Nikolcheva</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease</article-title>. <source>Alzheimers Research &amp; Therapy</source> <year>2017</year>, <volume>9</volume>.</mixed-citation></ref>
<ref id="c68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Honig</surname> <given-names>LS</given-names></string-name>, <string-name><surname>Vellas</surname> <given-names>B</given-names></string-name>, <string-name><surname>Woodward</surname> <given-names>M</given-names></string-name>, <string-name><surname>Boada</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bullock</surname> <given-names>R</given-names></string-name>, <string-name><surname>Borrie</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease</article-title>. <source>New England Journal of Medicine</source> <year>2018</year>, <volume>378</volume>(<issue>4</issue>): <fpage>321</fpage>–<lpage>330</lpage>.</mixed-citation></ref>
<ref id="c69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Henley</surname> <given-names>D</given-names></string-name>, <string-name><surname>Raghavan</surname> <given-names>N</given-names></string-name>, <string-name><surname>Sperling</surname> <given-names>R</given-names></string-name>, <string-name><surname>Aisen</surname> <given-names>P</given-names></string-name>, <string-name><surname>Raman</surname> <given-names>R</given-names></string-name>, <string-name><surname>Romano</surname> <given-names>G</given-names></string-name></person-group>. <article-title>Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer’s Disease</article-title>. <source>New England Journal of Medicine</source> <year>2019</year>, <volume>380</volume>(<issue>15</issue>): <fpage>1483</fpage>–<lpage>1485</lpage>.</mixed-citation></ref>
<ref id="c70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Egan</surname> <given-names>MF</given-names></string-name>, <string-name><surname>Kost</surname> <given-names>J</given-names></string-name>, <string-name><surname>Voss</surname> <given-names>T</given-names></string-name>, <string-name><surname>Mukai</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Aisen</surname> <given-names>PS</given-names></string-name>, <string-name><surname>Cummings</surname> <given-names>JL</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease</article-title>. <source>New England Journal of Medicine</source> <year>2019</year>, <volume>380</volume>(<issue>15</issue>): <fpage>1408</fpage>–<lpage>1420</lpage>.</mixed-citation></ref>
<ref id="c71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Panza</surname> <given-names>F</given-names></string-name>, <string-name><surname>Lozupone</surname> <given-names>M</given-names></string-name>, <string-name><surname>Logroscino</surname> <given-names>G</given-names></string-name>, <string-name><surname>Imbimbo</surname> <given-names>BP</given-names></string-name></person-group>. <article-title>A critical appraisal of amyloid-beta targeting therapies for Alzheimer disease</article-title>. <source>Nature Reviews Neurology</source> <year>2019</year>, <volume>15</volume>(<issue>2</issue>): <fpage>73</fpage>–<lpage>88</lpage>.</mixed-citation></ref>
<ref id="c72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wessels</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Lines</surname> <given-names>C</given-names></string-name>, <string-name><surname>Stern</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Kost</surname> <given-names>J</given-names></string-name>, <string-name><surname>Voss</surname> <given-names>T</given-names></string-name>, <string-name><surname>Mozley</surname> <given-names>LH</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Cognitive outcomes in trials of two BACE inhibitors in Alzheimer’s disease</article-title>. <source>Alzheimer’s &amp; dementia : the journal of the Alzheimer’s Association</source> <year>2020</year>, <volume>16</volume>(<issue>11</issue>): <fpage>1483</fpage>–<lpage>1492</lpage>.</mixed-citation></ref>
<ref id="c73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Novak</surname> <given-names>G</given-names></string-name>, <string-name><surname>Streffer</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Timmers</surname> <given-names>M</given-names></string-name>, <string-name><surname>Henley</surname> <given-names>D</given-names></string-name>, <string-name><surname>Brashear</surname> <given-names>HR</given-names></string-name>, <string-name><surname>Bogert</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study</article-title>. <source>Alzheimers Res Ther</source> <year>2020</year>, <volume>12</volume>(<issue>1</issue>): <fpage>58</fpage>.</mixed-citation></ref>
<ref id="c74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Timmers</surname> <given-names>M</given-names></string-name>, <string-name><surname>Streffer</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Russu</surname> <given-names>A</given-names></string-name>, <string-name><surname>Tominaga</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Shimizu</surname> <given-names>H</given-names></string-name>, <string-name><surname>Shiraishi</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study</article-title>. <source>Alzheimers Res Ther</source> <year>2018</year>, <volume>10</volume>(<issue>1</issue>): <fpage>85</fpage>.</mixed-citation></ref>
<ref id="c75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nigam</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ackermann</surname> <given-names>F</given-names></string-name>, <string-name><surname>Gregory</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Lundkvist</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lendahl</surname> <given-names>U</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Endogenous APP accumulates in synapses after BACE1 inhibition</article-title>. <source>Neuroscience research</source> <year>2016</year>, <volume>109</volume>: <fpage>9</fpage>–<lpage>15</lpage>.</mixed-citation></ref>
<ref id="c76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Citron</surname> <given-names>M</given-names></string-name></person-group>. <article-title>Emerging Alzheimer’s disease therapies: inhibition of beta-secretase</article-title>. <source>Neurobiol Aging</source> <year>2002</year>, <volume>23</volume>(<issue>6</issue>): <fpage>1017</fpage>–<lpage>1022</lpage>.</mixed-citation></ref>
<ref id="c77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Long</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Holtzman</surname> <given-names>DM</given-names></string-name></person-group>. <article-title>Alzheimer Disease: An Update on Pathobiology and Treatment Strategies</article-title>. <source>Cell</source> <year>2019</year>, <volume>179</volume>(<issue>2</issue>): <fpage>312</fpage>–<lpage>339</lpage>.</mixed-citation></ref>
<ref id="c78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Livingston</surname> <given-names>G</given-names></string-name>, <string-name><surname>Sommerlad</surname> <given-names>A</given-names></string-name>, <string-name><surname>Orgeta</surname> <given-names>V</given-names></string-name>, <string-name><surname>Costafreda</surname> <given-names>SG</given-names></string-name>, <string-name><surname>Huntley</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ames</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Dementia prevention, intervention, and care</article-title>. <source>Lancet</source> <year>2017</year>, <volume>390</volume>(<issue>10113</issue>): <fpage>2673</fpage>–<lpage>2734</lpage>.</mixed-citation></ref>
<ref id="c79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Butterfield</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Di Domenico</surname> <given-names>F</given-names></string-name>, <string-name><surname>Barone</surname> <given-names>E</given-names></string-name></person-group>. <article-title>Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain</article-title>. <source>Biochimica Et Biophysica Acta-Molecular Basis of Disease</source> <year>2014</year>, <volume>1842</volume>(<issue>9</issue>): <fpage>1693</fpage>–<lpage>1706</lpage>.</mixed-citation></ref>
<ref id="c80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arnold</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Arvanitakis</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Macauley-Rambach</surname> <given-names>SL</given-names></string-name>, <string-name><surname>Koenig</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>H-Y</given-names></string-name>, <string-name><surname>Ahima</surname> <given-names>RS</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums</article-title>. <source>Nature Reviews Neurology</source> <year>2018</year>, <volume>14</volume>(<issue>3</issue>): <fpage>168</fpage>–<lpage>181</lpage>.</mixed-citation></ref>
<ref id="c81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname> <given-names>QY</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>XH</given-names></string-name>, <string-name><surname>Yan</surname> <given-names>S</given-names></string-name>, <string-name><surname>Xie</surname> <given-names>XF</given-names></string-name>, <string-name><surname>Fan</surname> <given-names>YH</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>JQ</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>The antidepressant-like effects of pioglitazone in a chronic mild stress mouse model are associated with PPAR gamma-mediated alteration of microglial activation phenotypes</article-title>. <source>Journal of neuroinflammation</source> <year>2016</year>, <volume>13</volume>.</mixed-citation></ref>
<ref id="c82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guo</surname> <given-names>M</given-names></string-name>, <string-name><surname>Li</surname> <given-names>C</given-names></string-name>, <string-name><surname>Lei</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>D</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>XY</given-names></string-name></person-group>. <article-title>Role of the adipose PPAR gamma-adiponectin axis in susceptibility to stress and depression/anxiety-related behaviors</article-title>. <source>Molecular Psychiatry</source> <year>2017</year>, <volume>22</volume>(<issue>7</issue>): <fpage>1056</fpage>–<lpage>1068</lpage>.</mixed-citation></ref>
<ref id="c83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Toledo</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Inestrosa</surname> <given-names>NC</given-names></string-name></person-group>. <article-title>Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer’s disease</article-title>. <source>Mol Psychiatry</source> <year>2010</year>, <volume>15</volume>(<issue>3</issue>): <fpage>272</fpage>–<lpage>285</lpage>, 228.</mixed-citation></ref>
<ref id="c84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Escribano</surname> <given-names>L</given-names></string-name>, <string-name><surname>Simón</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Gimeno</surname> <given-names>E</given-names></string-name>, <string-name><surname>Cuadrado-Tejedor</surname> <given-names>M</given-names></string-name>, <string-name><given-names>López</given-names> <surname>de Maturana R</surname></string-name>, <string-name><surname>García-Osta</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Rosiglitazone rescues memory impairment in Alzheimer’s transgenic mice: mechanisms involving a reduced amyloid and tau pathology</article-title>. <source>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</source> <year>2010</year>, <volume>35</volume>(<issue>7</issue>): <fpage>1593</fpage>–<lpage>1604</lpage>.</mixed-citation></ref>
<ref id="c85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Reilly</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Lynch</surname> <given-names>M</given-names></string-name></person-group>. <article-title>Rosiglitazone improves spatial memory and decreases insoluble Aβ(1-42) in APP/PS1 mice</article-title>. <source>Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology</source> <year>2012</year>, <volume>7</volume>(<issue>1</issue>): <fpage>140</fpage>–<lpage>144</lpage>.</mixed-citation></ref>
<ref id="c86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Watson</surname> <given-names>GS</given-names></string-name>, <string-name><surname>Cholerton</surname> <given-names>BA</given-names></string-name>, <string-name><surname>Reger</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Baker</surname> <given-names>LD</given-names></string-name>, <string-name><surname>Plymate</surname> <given-names>SR</given-names></string-name>, <string-name><surname>Asthana</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study</article-title>. <source>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</source> <year>2005</year>, <volume>13</volume>(<issue>11</issue>): <fpage>950</fpage>–<lpage>958</lpage>.</mixed-citation></ref>
<ref id="c87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tzimopoulou</surname> <given-names>S</given-names></string-name>, <string-name><surname>Cunningham</surname> <given-names>VJ</given-names></string-name>, <string-name><surname>Nichols</surname> <given-names>TE</given-names></string-name>, <string-name><surname>Searle</surname> <given-names>G</given-names></string-name>, <string-name><surname>Bird</surname> <given-names>NP</given-names></string-name>, <string-name><surname>Mistry</surname> <given-names>P</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>A multi-center randomized proof-of-concept clinical trial applying [¹F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer’s disease</article-title>. <source>Journal of Alzheimer’s disease : JAD</source> <year>2010</year>, <volume>22</volume>(<issue>4</issue>): <fpage>1241</fpage>–<lpage>1256</lpage>.</mixed-citation></ref>
<ref id="c88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harrington</surname> <given-names>C</given-names></string-name>, <string-name><surname>Sawchak</surname> <given-names>S</given-names></string-name>, <string-name><surname>Chiang</surname> <given-names>C</given-names></string-name>, <string-name><surname>Davies</surname> <given-names>J</given-names></string-name>, <string-name><surname>Donovan</surname> <given-names>C</given-names></string-name>, <string-name><surname>Saunders</surname> <given-names>AM</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer’s disease: two phase 3 studies</article-title>. <source>Current Alzheimer research</source> <year>2011</year>, <volume>8</volume>(<issue>5</issue>): <fpage>592</fpage>–<lpage>606</lpage>.</mixed-citation></ref>
<ref id="c89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Keating</surname> <given-names>GM</given-names></string-name>, <string-name><surname>Croom</surname> <given-names>KF</given-names></string-name></person-group>. <article-title>Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus</article-title>. <source>Drugs</source> <year>2007</year>, <volume>67</volume>(<issue>1</issue>): <fpage>121</fpage>–<lpage>153</lpage>.</mixed-citation></ref>
<ref id="c90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barbiero</surname> <given-names>JK</given-names></string-name>, <string-name><surname>Santiago</surname> <given-names>R</given-names></string-name>, <string-name><surname>Tonin</surname> <given-names>FS</given-names></string-name>, <string-name><surname>Boschen</surname> <given-names>S</given-names></string-name>, <string-name><surname>da Silva</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Werner</surname> <given-names>MF</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson’s disease</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> <year>2014</year>, <volume>53</volume>: <fpage>35</fpage>–<lpage>44</lpage>.</mixed-citation></ref>
<ref id="c91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ouk</surname> <given-names>T</given-names></string-name>, <string-name><surname>Gautier</surname> <given-names>S</given-names></string-name>, <string-name><surname>Pétrault</surname> <given-names>M</given-names></string-name>, <string-name><surname>Montaigne</surname> <given-names>D</given-names></string-name>, <string-name><surname>Maréchal</surname> <given-names>X</given-names></string-name>, <string-name><surname>Masse</surname> <given-names>I</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Effects of the PPAR-α agonist fenofibrate on acute and short-term consequences of brain ischemia</article-title>. <source>Journal of Cerebral Blood Flow &amp; Metabolism</source> <year>2014</year>, <volume>34</volume>(<issue>3</issue>): <fpage>542</fpage>–<lpage>551</lpage>.</mixed-citation></ref>
<ref id="c92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Assaf</surname> <given-names>N</given-names></string-name>, <string-name><surname>El-Shamarka</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Salem</surname> <given-names>NA</given-names></string-name>, <string-name><surname>Khadrawy</surname> <given-names>YA</given-names></string-name>, <string-name><surname>El Sayed</surname> <given-names>NS</given-names></string-name></person-group>. <article-title>Neuroprotective effect of PPAR alpha and gamma agonists in a mouse model of amyloidogenesis through modulation of the Wnt/beta catenin pathway via targeting alpha- and beta-secretases</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> <year>2020</year>, <volume>97</volume>: <fpage>109793</fpage>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.99462.2.sa4</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ye</surname>
<given-names>Keqiang</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Chinese Academy of Sciences</institution>
</institution-wrap>
<city>Shenzhen</city>
<country>China</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Convincing</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Important</kwd>
</kwd-group>
</front-stub>
<body>
<p>This <bold>important</bold> study identified a molecular mechanism linking diabetes to AD risk and the data presented are <bold>convincing</bold>. The authors investigated the role of kallistatin in metabolic abnormalities associated with AD and identified that Kallistatin is a key player that mediates Aβ accumulation and tau hyperphosphorylation in AD. This manuscript provides novel insights into the pathogenesis of AD, indicating that the hypolipidemic drug fenofibrate attenuates AD-like pathology in Kallistatin transgenic mice.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.99462.2.sa3</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>Qi and colleagues investigated the role of Kallistatin pathway in increasing hippocampal amyloid-β plaques accumulation and tau hyperpholphorylation in Alzheimer's disease, linking the increased Kallistatin level in diabetic patients with a higher risk of Alzheimer's disease development. A Kallistatin overexpressing animal model was utilized, and memory impairment was assessed using Morris water maze and Y-maze. Kallistatin-related pathway protein levels were measured in the hippocampus, and phenotypes were rescued using fenofibrate and rosiglitazone. The current study provides evidence of a novel molecular mechanism linking diabetes and Alzheimer's disease, and suggests the potential use of fenofibrate to alleviate memory impairment. However, several issues need to be addressed before further consideration.</p>
<p>Strengths:</p>
<p>The finding of this study is novel. The finding will have great impacts on diabetes and AD research. The studies were well conducted, and results convincing.</p>
<p>Weaknesses:</p>
<p>(1) The mechanism by which fenofibrate rescues memory loss in Kallistatin-transgenic mice is unclear. As a PPARα agonist, does fenofibrate target the Kallistatin pathway directly or indirectly? Please provide discussion based on literature supporting either possibility.</p>
<p>
(2) The current study exclusively investigated hippocampus. What about other cognitive memory-related regions, such as prefrontal cortex? Including data from these regions or discussing the possibility of their involvement could provide a more comprehensive understanding of the role of Kallistatin in memory impairment.</p>
<p>
(3) Fenofibrate rescued phenotypes in Kallistatin-transgenic mice while rosiglitazone, a PPARα agonist, did not. This result contradicts the manuscript's emphasis on a PPARα-associated mechanism. Please address this inconsistency.</p>
<p>
(4) Most of the immunohistochemistry images are unclear. Inserts have similar magnification to the original representative images, making judgments difficult. Please provide larger inserts with higher resolution.</p>
<p>
(5) The immunohistochemistry images in different figures were taken from different hippocampal subregions with different magnifications. Please maintain consistency, or explain why CA1, CA3 or DG was analyzed in each experiment.</p>
<p>
(6) Figure 5B is missing a title. Please add a title to maintain consistency with other graphs.</p>
<p>
(7) Please list statistical methods used in the figure legends, such as t-test or One way ANOVA with post-hoc tests.</p>
<p>Comments on revisions:</p>
<p>The authors have addressed the issues raised from the review. The manuscript has been revised accordingly.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.99462.2.sa2</article-id>
<title-group>
<article-title>Reviewer #2 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>The study links Alzheimer's disease (AD) with metabolic disorders through elevated Kallistatin levels in AD patients. Kallistatin-overexpressing mice show cognitive decline, increased Aβ and tau pathology, and impaired hippocampal function. Mechanistically, Kallistatin enhances Aβ production via Notch1 and promotes tau phosphorylation through GSK-3β activation. Fenofibrate improves cognitive deficits by reducing Aβ and tau phosphorylation in these mice, suggesting therapeutic potential in AD linked to metabolic syndromes.</p>
<p>Strengths:</p>
<p>This study presents a novel insights into Alzheimer's disease (AD) pathogenesis and provides strong evidences about the mechanistic roles of Kallistatin and the therapeutic potential of fenofibrate in AD.</p>
<p>It was suggested that Kallistatin is primarily produced by the liver. The study demonstrates increased Kallistatin levels in the hippocampus tissue of AD mice. They also found that Kallistatin is also increased in the liver of AD mice.</p>
<p>They also showed that Kallistatin directly binds to Notch1 and contributes to the activation of the Noch1-HES1 signaling pathway</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.99462.2.sa1</article-id>
<title-group>
<article-title>Reviewer #3 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>The authors investigated the role of kallistatin in metabolic abnormalities associated with AD. They found that Kallistatin promotes Aβ production by binding to the Notch1 receptor and upregulating BACE1 expression. They identified that Kallistatin is a key player that mediates Aβ accumulation and tau hyperphosphorylation in AD.</p>
<p>Strengths:</p>
<p>This manuscript not only provides novel insights into the pathogenesis of AD, but also indicates that the hypolipidemic drug fenofibrate attenuates AD-like pathology in Kallistatin transgenic mice.</p>
<p>Weaknesses:</p>
<p>The authors did not illustrate whether the protective effect of fenofibrate against AD depends on kallistatin.</p>
<p>The conclusions are supported by the results.</p>
</body>
</sub-article>
<sub-article id="sa4" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.99462.2.sa0</article-id>
<title-group>
<article-title>Author response:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Qi</surname>
<given-names>Weiwei</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Long</surname>
<given-names>Yanlan</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Ziming</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Zhen</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shi</surname>
<given-names>Jinhui</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xie</surname>
<given-names>Wanting</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Laijian</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tan</surname>
<given-names>Yandan</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Ti</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8517-5405</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Liang</surname>
<given-names>Minting</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jiang</surname>
<given-names>Ping</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jiang</surname>
<given-names>Bin</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Xia</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gao</surname>
<given-names>Guoquan</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8996-1470</contrib-id></contrib>
</contrib-group>
</front-stub>
<body>
<p>The following is the authors’ response to the original reviews</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #1:</bold></p>
<p>(1) The mechanism by which fenofibrate rescues memory loss in Kallistatin-transgenic mice is unclear. As a PPARalpha agonist, does fenofibrate target the Kallistatin pathway directly or indirectly? Please provide a discussion based on literature supporting either possibility.</p>
</disp-quote>
<p>Thank you for your important suggestion. Fenofibrate is indeed acting as a PPARα agonist. Fenofibrate has been shown to protect memory and cognitive function by downregulating α- and β-secretases[1]. Activation of PPARα can reduce Aβ plaques by upregulating ADAM10, thereby protecting memory and cognition[2]. Whereas, Fenofibrate can also act through a PPARα-independent pathway[3]. In our previous study, we proved that Fenofibrate can directly down-regulate the expression of Kallistatin in hepatocytes[4]. Here, our findings showed that Kallistatin induces cognitive memory deterioration by increasing amyloid-β plaques accumulation and tau protein hyperphosphorylation (Fig. 1-3), and Fenofibrate can directly down-regulate the serum level of Kallistatin (Fig. 8G). In addition, the expression of PPARα in the hippocampal tissue of Kallistatin (KAL-TG) mice showed no significant difference compared to the WT group (Author response image 1A-B). Therefore, we think Fenofibrate may improve memory and cognitive function at least in part through a PPARα-independent effect, which provides a new mechanism of Fenofibrate in AD with elevated Kallistatin levels.</p>
<fig id="sa4fig1">
<label>Author response image 1.</label>
<caption>
<title>(A-B) Protein levels of PPARα were tested by western blot analysis in hippocampal tissue, then statistically analyzed the above results.</title>
</caption>
<graphic mime-subtype="jpg" xlink:href="elife-99462-sa4-fig1.jpg" mimetype="image"/>
</fig>
<disp-quote content-type="editor-comment">
<p>(2) The current study exclusively investigated the hippocampus. What about other cognitive memory-related regions, such as the prefrontal cortex? Including data from these regions or discussing the possibility of their involvement could provide a more comprehensive understanding of the role of Kallistatin in memory impairment.</p>
</disp-quote>
<p>Thank you for your suggestion. In addition to hippocampal tissue analysis, we performed immunohistochemical detection of Aβ and phosphorylated Tau levels in the prefrontal cortex. Our findings revealed that KAL-TG mice exhibited significantly elevated Aβ and phosphorylated Tau levels in the prefrontal cortex compared to WT mice. These observations align with the pathological patterns observed in hippocampal tissues, demonstrating consistent neurodegenerative pathology across both the hippocampus and prefrontal cortex. The data for this part are seen as follows.</p>
<fig id="sa4fig2">
<label>Author response image 2.</label>
<caption>
<title>(A-B) Immunofluorescence staining of Aβ and phosphorylated tau (p-tau T231) was carried out in the prefrontal cortex tissue of KAL-TG and WT mice.</title>
<p>Error bars represented the Standard Error of Mean (SEM); **<italic>p</italic> &lt; 0.01. <italic>Scale bar</italic>, 100 μm.</p>
</caption>
<graphic mime-subtype="jpg" xlink:href="elife-99462-sa4-fig2.jpg" mimetype="image"/>
</fig>
<disp-quote content-type="editor-comment">
<p>(3) Fenofibrate rescued phenotypes in Kallistatin-transgenic mice while rosiglitazone, a PPARgamma agonist, did not. This result contradicts the manuscript's emphasis on a PPARgamma-associated mechanism. Please address this inconsistency.</p>
</disp-quote>
<p>Thank you for the reminder. In fact, our results showed a trend towards improved memory and cognitive function in KAL-TG mice treated with Rosiglitazone, although its effect is not as significant as that of Fenofibrate. Several studies have reported that Rosiglitazone has a beneficial effect on memory and cognitive function in mouse models of dementia, while these studies involve treatment periods of 3 to 4 months[5, 6], whereas our treatment period was only one month. Extending the treatment period with Rosiglitazone may result in a more pronounced improvement. In addition, Fenofibrate may have a PPAR-independent pathway by downregulating Kallistatin directly as discussed above and then show stronger effects.</p>
<disp-quote content-type="editor-comment">
<p>(4) Most of the immunohistochemistry images are unclear. Inserts have similar magnification to the original representative images, making judgments difficult. Please provide larger inserts with higher resolution.</p>
</disp-quote>
<p>According to your suggestion, we provided larger inserts with higher resolution in Fig 3A and Fig 4B, as follows:</p>
<disp-quote content-type="editor-comment">
<p>(5) The immunohistochemistry images in different figures were taken from different hippocampal subregions with different magnifications. Please maintain consistency, or explain why CA1, CA3, or DG was analyzed in each experiment.</p>
</disp-quote>
<p>Thank you for your advice. The trends of changes in different brain regions(including CA1, CA3, or DG) are consistent. Following your suggestion, we have now selected the DG region replaced the different hippocampal subregions with the DG area, and re-conducted the statistical analysis in Fig 5I &amp; 6C, as follows. Due to the significant deposition of Aβ only in the CA1 region, Fig 2A was not replaced.</p>
<disp-quote content-type="editor-comment">
<p>(6) Figure 5B is missing a title. Please add a title to maintain consistency with other graphs.</p>
</disp-quote>
<p>Thanks for your suggestion. We have added a title to Figure 5B, as follows:</p>
<disp-quote content-type="editor-comment">
<p>(7) Please list statistical methods used in the figure legends, such as t-test or One-way ANOVA with post-hoc tests.</p>
</disp-quote>
<p>Thanks for your suggestion. We have listed the statistical methods used in the figure legends.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2:</bold></p>
<p>(1) It was suggested that Kallistatin is primarily produced by the liver. The study demonstrates increased Kallistatin levels in the hippocampus tissue of AD mice. It would be valuable to clarify if Kallistatin is also increased in the liver of AD mice, providing a comprehensive understanding of its distribution in disease states.</p>
</disp-quote>
<p>Thank you for your suggestion. We extracted liver tissue from APP/PS1 mice, and the Western blot results indicated that the expression of Kallistatin in the liver of APP/PS1 mice was elevated, as follows:</p>
<fig id="sa4fig3">
<label>Author response image 3.</label>
<caption>
<title>(A-B) Protein levels of Kallistatin were tested by western blot analysis in the liver tissue, then statistically analyzed the above results.</title>
<p>Error bars represented the Standard Error of Mean (SEM); **<italic>p</italic> &lt; 0.01.</p>
</caption>
<graphic mime-subtype="jpg" xlink:href="elife-99462-sa4-fig3.jpg" mimetype="image"/>
</fig>
<disp-quote content-type="editor-comment">
<p>(2) Does Kallistatin interact directly with Notch1 ligands? Clarifying this interaction mechanism would enhance understanding of how Kallistatin influences Notch1 signaling in AD pathology.</p>
</disp-quote>
<p>Thank you for your suggestion. This study reveals that Kallistatin directly binds to Notch1 and contributes to the activation of the Noch1-HES1 signaling pathway. As for whether Kallistatin can bind to the ligands of Notch1, it needs to conduct further investigations in future studies. Our preliminary data showed that Jagged1 was upregulated in the hippocampal tissues of KAL-TG mice by qPCR and Western blot analyses.</p>
<fig id="sa4fig4">
<label>Author response image 4.</label>
<caption>
<title>Kallistatin promoted Notch ligand Jagged1 expression to activate Notch1 signaling.</title>
<p>(A) QPCR analysis of Notch ligands (Dll1, Dll3, Jagged1, Jagged2) expression in the 9 months hippocampus tissue. (B) Western blotting analysis of Notch ligand Jagged1 expression in the hippocampus tissue. (C) Western blotting analysis of Notch ligand Jagged1 expression in the hippocampus primary neuron. β-actin served as the loading control. Error bars represented the Standard Error of Mean (SEM); *<italic>p</italic> &lt; 0.05.</p>
</caption>
<graphic mime-subtype="jpg" xlink:href="elife-99462-sa4-fig4.jpg" mimetype="image"/>
</fig>
<disp-quote content-type="editor-comment">
<p>(3) Is there any observed difference in AD phenotype between male and female Kallistatin-transgenic (KAL-TG) mice? Including this information would address potential gender-specific effects on cognitive decline and pathology.</p>
</disp-quote>
<p>Thank you for your suggestion. Actually, we have previously used female mice for Morris Water Maze experiments, and the results showed that both male and female KAL-TG mice exhibited a phenotype of decreased memory and cognitive function compared to the gender-matched WT group, while there was no significant difference between male and female KAL-TG mice as follows:</p>
<fig id="sa4fig5">
<label>Author response image 5.</label>
<caption>
<title>(A-D) Behavioral performance was assessed through the Morris water maze test.</title>
<p>(A) The escape latency time was presented during 1-5 days. (B-D) Cognitive functions were evaluated by spatial probe test on day 6, then analyzing each group of mice crossing platform times(B), time percent in the targeted area (C), and the path traces heatmap (D). Error bars represented the Standard Error of Mean (SEM); F represents Female, M represents Male, and TG refers to KAL-TG; *<italic>p</italic> &lt; 0.05.</p>
</caption>
<graphic mime-subtype="jpg" xlink:href="elife-99462-sa4-fig5.jpg" mimetype="image"/>
</fig>
<disp-quote content-type="editor-comment">
<p>(4) It is recommended to include molecular size markers in Western blots for clarity and accuracy in protein size determination.</p>
</disp-quote>
<p>Thank you for your reminder. We have shown the molecular weight of each bolt.</p>
<disp-quote content-type="editor-comment">
<p>(5) The language should be revised for enhanced readability and clarity, ensuring that complex scientific concepts are communicated effectively to a broader audience.</p>
</disp-quote>
<p>According to your suggestion, we have polished the article for enhancing readability and clarity.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #3:</bold></p>
<p>(1) The authors did not illustrate whether the protective effect of fenofibrate against AD depends on Kallistatin.</p>
</disp-quote>
<p>Thank you for your important suggestion. Fenofibrate is indeed acting as a PPARα agonist. Fenofibrate has been shown to protect memory and cognitive function by downregulating α- and β-secretases[1]. Activation of PPARα can reduce Aβ plaques by upregulating ADAM10, thereby protecting memory and cognition[2]. Whereas, Fenofibrate can also act through a PPARα-independent pathway[3]. In our previous study，we proved Fenofibrate can directly down-regulate the expression of KAL in hepatocytes[4]. Here, our findings showed that Kallistatin induces cognitive memory deterioration by increasing amyloid-β plaques accumulation and tau protein hyperphosphorylation (Fig. 1-3), and Fenofibrate can directly down-regulate the serum level of Kallistatin (Fig. 8G). In addition, the expression of PPARα in the hippocampal tissue of Kallistatin (KAL-TG) mice showed no significant difference compared to the WT group (Author response image 1-B). Therefore, we think Fenofibrate may improve memory and cognitive function at least in part through downregulatin Kallistatin. To conclusively determine whether fenofibrate’s therapeutic effects depend on Kallistatin, future studies should employ Kallistatin-knockout AD animal models to evaluate fenofibrate’s impact on cognitive and memory functions. These investigations will further clarify the mechanistic underpinnings of fenofibrate in AD therapy.</p>
<disp-quote content-type="editor-comment">
<p>(2) The conclusions are supported by the results, but the quality of some results should be improved.</p>
</disp-quote>
<p>Thank you for your kind suggestion. We have updated the magnified images in the immunohistochemistry section of the article, ensuring that the fields of view for the immunohistochemistry are within the same brain region, and have shown the molecular weights in each bolt. Additionally, we have conducted a quantitative analysis of the protein levels in the Western blot results presented in Fig6&amp;8.</p>
<disp-quote content-type="editor-comment">
<p>(3) Figures 2c, 3c, and 4a present the Western blot results of p-tau from mice of different ages on one membrane, showing age-dependent expression. The authors analyzed the results of mice of different ages in one statistical chart, which will create ambiguity with the results of the representative images. For example, the expression of p-tau 396 in the blot was lower in the WT-12 M group than in the WT-9 M group (Figure 3c), which is contradictory to the statistical analysis.</p>
</disp-quote>
<p>Thank you for your reminder. The statistical presentation here does not match the figure. At that time, the WB experiments for the hippocampal tissue at each age group were conducted separately, and it was not appropriate to compare different age groups together. This graph cannot illustrate age dependency. We have replaced the statistical graph in Figure 3B&amp;D, as follows:</p>
<disp-quote content-type="editor-comment">
<p>(4) Figure 4b shows that KAL-TG-9 M had greater BACE1 expression than KAL-TG-12 M. Furthermore, the nuclei are not uniformly colored. Please provide more representative figures.</p>
</disp-quote>
<p>Thank you for your reminder. Due to the fact that these sets of data were not processed in a single batch, the ages in the graph are not comparable. Regarding the issue of inconsistent nuclear staining, we have provided another representative image from this group, as follows:</p>
<disp-quote content-type="editor-comment">
<p>(5) Unclear why the BACE1 and Aβ levels seems less with KAL+shHES1 treatment than GFP+shNC treatment (Fig 6H)? This finding contradicts the conclusion.</p>
</disp-quote>
<p>Thank you for your reminder. This experiment was repeated three times, and here, we have represented the representative results along with the corresponding statistical data. There are no difference between KAL+shHES1 treatment and GFP+shNC treatment. We have updated the Fig. 6H.</p>
<disp-quote content-type="editor-comment">
<p>(6) The Western blot results in figure 6e-h, 8h-i, and S3-S5 were not quantified.</p>
</disp-quote>
<p>Thank you for your reminder. We have added statistical graphs and original images of the pictures in figure 6e-h, 8h-i, and S3-S5.</p>
<disp-quote content-type="editor-comment">
<p>(7) The authors did not provide the detection range of the Aβ42 ELISA kit.</p>
</disp-quote>
<p>Thank you for your suggestion. The Aβ42 ELISA kit is from the IBL, with the product number 27721. Its standard range is 1.56 - 100 pg/mL, and the sensitivity is 0.05 pg/mL.</p>
<disp-quote content-type="editor-comment">
<p>(8)The authors did not specify the sex of the mice. This is important since sex could have had a dramatic impact on the results.</p>
</disp-quote>
<p>Thank you for your suggestion. The results we present in the text are all statistically obtained from male mice. Actually, we have previously used female mice for Morris Water Maze experiments, and the results showed that both male and female KAL-TG mice exhibited a phenotype of decreased memory and cognitive function compared to the gender-matched WT group, while there was no significant difference between male and female KAL-TG mice (Author response image 5).</p>
<disp-quote content-type="editor-comment">
<p>Minor:</p>
<p>(1) In Figure 2b, there are no units for the vertical coordinates of the statistical graph.</p>
</disp-quote>
<p>Thank you for your reminder. We have added units for the vertical coordinates in Figure 2b.</p>
<disp-quote content-type="editor-comment">
<p>(2) In Figure 2c, the left Y-axis title is lacking in the statistic chart.</p>
</disp-quote>
<p>Thank you for your reminder. We have added the left Y-axis title in the statistic chart.</p>
<p>Reference：</p>
<p>(1) Assaf N, El-Shamarka ME, Salem NA, Khadrawy YA, El Sayed NS. Neuroprotective effect of PPAR alpha and gamma agonists in a mouse model of amyloidogenesis through modulation of the Wnt/beta catenin pathway via targeting alpha- and beta-secretases. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2020, 97: 109793.</p>
<p>(2) Rangasamy SB, Jana M, Dasarathi S, Kundu M, Pahan K. Treadmill workout activates PPARα in the hippocampus to upregulate ADAM10, decrease plaques and improve cognitive functions in 5XFAD mouse model of Alzheimer’s disease. Brain, Behavior, and Immunity 2023, 109: 204-218.</p>
<p>(3) Yuan J, Tan JTM, Rajamani K, Solly EL, King EJ, Lecce L, et al. Fenofibrate Rescues Diabetes-Related Impairment of Ischemia-Mediated Angiogenesis by PPARα-Independent Modulation of Thioredoxin-Interacting Protein. Diabetes 2019, 68(5): 1040-1053.</p>
<p>(4) Fang Z, Shen G, Wang Y, Hong F, Tang X, Zeng Y, et al. Elevated Kallistatin promotes the occurrence and progression of non-alcoholic fatty liver disease. Signal Transduct Target Ther 2024, 9(1): 66.</p>
<p>(5) Nelson ML, Pfeifer JA, Hickey JP, Collins AE, Kalisch BE. Exploring Rosiglitazone's Potential to Treat Alzheimer's Disease through the Modulation of Brain-Derived Neurotrophic Factor. Biology (Basel) 2023, 12(7).</p>
<p>(6) Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 2006, 199(2): 265-273.</p>
</body>
</sub-article>
</article>